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Abstract
The purpose of this work was to compare the cytogenetic effects of densely
and sparsely ionizing radiations in vitro and in vivo. To achieve this, chromo-
somal aberrations in peripheral blood lymphocytes were exposed in vitro to
different doses of X-rays and C-ions with different energies; furthermore, lym-
phocytes were obtained from prostate-cancer patients before, during and after
radiotherapy and analyzed using the multiplex fluorescence in situ hybridiza-
tion (mFISH) technique. These cancer patients were either treated with C-ion
boost irradiation in the course of a conventional photon intensity-modulated
radiotherapy (IMRT) or solely with IMRT. Blood samples were taken from
each patient before, during, at the end of and one year after the therapy.
In the in vitro experiments, an increase in the relative biological effec-
tiveness (RBE) for the induction of chromosomal aberrations with increas-
ing linear energy transfer (LET) of the C-ions was observed in the investi-
gated energy range (270 MeV/u C-ions, LET=14 keV/µm; 100 MeV/u C-ions,
LET=29 keV/µm; extended Bragg peak of C-ions, LET=60–85 keV/µm). The
ratio of complex to simple exchanges, the C-ratio, which is discussed as a
biomarker for densely ionizing radiation, was calculated and a LET- and dose-
dependent increase was found. Likewise, the complexity of complex chromo-
some aberrations increased with LET and dose.
For prostate-cancer patients, the frequency of chromosomal aberrations
found in the peripheral blood lymphocytes increased during the radiotherapy
course; but after the C-ion boost, the frequency was lower than in patients
treated with comparable doses of IMRT. No significantly increased C-ratio
was found in the patients treated with the C-ion boost compared to the pa-
tients treated with IMRT. A higher frequency of aberrations was measured
in patients who were exposed to an increased target volume. The aberration
frequency decreased significantly in two out of 16 patients in the year after
therapy.
The study shows that the reduced integral dose applied to normal tissue dur-
ing the C-ion boost is reflected in a lower chromosomal aberration frequency
compared to IMRT. While the in vitro experiments showed an enhanced C-
ratio for densely ionizing radiation, no increased C-ratio was observed in the
patients’ samples after C-ion boost therapy.
As mFISH allows identification of individual chromosomes involved in aber-
rations, the distribution of breakpoints among individual chromosomes and
the frequencies of pairwise chromosomal exchanges were analyzed in addition.
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Zusammenfassung
Ziel dieser Arbeit war es, die zytogenetischen Effekte von dicht und du¨nn io-
nisierender Strahlung in vitro und in vivo zu vergleichen. Dazu wurden Chro-
mosomenaberrationen in peripheren Blutlymphozyten in vitro mit verschie-
denen Dosen Ro¨ntgenstrahlung und C-Ionen verschiedener Energien bestrahlt
sowie Lymphozyten von Prostatakarzinompatienten vor, wa¨hrend und nach
der Strahlentherapie entnommen und mittels mFISH (multiplex fluorescence
in situ hybridization) untersucht. Die Prostatakarzinompatienten wurden mit
einer Kombination aus C-Ionen Bestrahlung und anschließender intensita¨ts-
modulierter Strahlentherapie (IMRT) oder ausschließlich mit IMRT behan-
delt.
In den in vitro Experimenten wurde ein Anstieg der relativen biolo-
gischen Wirksamkeit (RBE) fu¨r Chromosomenaberrationen mit steigen-
dem linearen Energietransfer (LET) innerhalb des untersuchten Energiebe-
reichs gefunden (270 MeV/u C-Ionen, LET=14 keV/µm; 100 MeV/u C-Ionen,
LET=29 keV/µm; ausgedehnter C-Ionen Bragg-Peak, LET=60–85 keV/µm).
Das Verha¨ltnis von komplexen zu einfachen Chromosomenaustauschen, ge-
nannt C-ratio, welches als Biomarker fu¨r dicht ionisierende Strahlung disku-
tiert wird, wurde ermittelt und ein Dosis- und LET-abha¨ngiger Anstieg wurde
beobachtet. Ebenso stieg die Komplexita¨t komplexer Chromosomenaberratio-
nen mit Dosis und LET an.
Die Aberrationsrate, die in den Blutlymphozyten von Prostatakarzinompa-
tienten gefunden wurde erho¨hte sich im Verlauf der Strahlentherapie. Nach
der C-Ionen-Bestrahlung war die Abberationsrate geringer als in Patienten
die mit einer vergleichbaren Dosis IMRT bestrahlt wurden. Die C-ratio war
in den mit C-Ionen bestrahlten Patienten im Vergleich zu den IMRT Patienten
nicht signifikant erho¨ht. In Patienten, welche mit einem gro¨ßeren Zielvolumen
bestrahlt wurden, war die Aberrationsrate signifikant ho¨her. Im Jahr nach der
Therapie wurde ein signifikanter Ru¨ckgang der Aberrationsrate in zwei von
16 Patienten beobachtet.
Die Studie zeigt, dass sich die niedrigere integrale Dosis, die bei der Kohlen-
stoffionen-Therapie im Normalgewebe appliziert wird, durch eine niedrigere
Aberrationsrate, verglichen mit IMRT, auswirkt. Wa¨hrend nach in vitro Be-
strahlung ein ho¨herer Anteil komplexer Aberrationen nach Bestrahlung mit
dicht ionisierender Strahlung gefunden wurde, konnte ein solcher Effekt in
vivo in Patienten, die sich einer Kohlenstoffionen-Therapie unterzogen, nicht
gezeigt werden.
Da es mit der mFISH Fa¨rbung mo¨glich ist alle Chromosomen, die an Ab-
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errationen beteiligt sind, zu identifizieren, wurde die Verteilung der Bruch-
punkte in den einzelnen Chromosomen sowie die Ha¨ufigkeit von Austauschen
zwischen allen Chromosomenpaaren untersucht.
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1. Introduction
1.1. Motivation
The purpose of this work was to gain more insight in the cytogenetic effects of
densely ionizing radiation and in the application of aberration analysis in bi-
ological dosimetry. For this, the chromosomal aberrations induced by densely
and sparsely ionizing radiation in vitro and in vivo were analyzed using the
high-resolution multiplex fluorescence in situ hybridization (mFISH) staining
technique. Biological dosimetry of exposure to densely ionizing radiation be-
comes increasingly important because of the increasing use of particle therapy
for cancer treatment [Kraft and Kraft, 2009; Schulz-Ertner, 2009; Durante and
Loeﬄer, 2010]. In addition, the exposure to galactic cosmic radiation (which
includes densely ionizing particles) is one of the major problems for long-term
manned space missions [Durante and Cucinotta, 2008].
With the mFISH technique the aberration spectrum can be analyzed with
high resolution. For this study, mFISH was essential mainly for two rea-
sons: the search for a cytogenetic signature (”fingerprint”) of the heavy ion
irradiation, and the analysis of transmissible aberrations. By analyzing LET-
dependent changes in the aberration spectrum, information about possible
cytogenetic biomarkers is obtained.
Transmissible aberrations are important regarding the late effects of radia-
tion exposure. In tumor therapy, bone marrow, which contains the stem cells,
is often unavoidably exposed to radiation. Cytogenetically aberrant stem cells
can pass transmissible aberrations to their daughter cells and thus increase
the risk of secondary cancers. Progenies of aberrant bone marrow cells can be
found in the peripheral blood lymphocytes, and are the reason why a radiation
exposure can be detected decades after the exposure by an enhanced yield of
transmissible aberrations in the peripheral blood lymphocytes [Kleinerman
et al., 1989]. In the present study, mFISH was applied to the lymphocytes of
cancer patients undergoing radiotherapy to study the influence of different ra-
diotherapy regimens and to detect changes in the aberration spectrum in the
year after therapy. A change in the aberration spectrum towards transmissi-
ble aberrations indicates that bone marrow was exposed. When transmissible
aberrations are induced in stem cells, these cells produce aberrant progenies
which mature to lymphocytes (and other cell types).In contrast, the originally
irradiated cells (carrying transmissible and non-transmissible aberrations) de-
cline with time.
1
2 Chapter 1. Introduction
For the in vitro experiments, human peripheral blood lymphocytes were
exposed to C-ions with different energies to measure dose-effect curves for the
induction of chromosomal aberrations. X-ray experiments were performed for
comparison. Dose-effect curves are a useful tool for biological dosimetry in
case of an accidental, occupational or medical exposure of an individual to
sparsely or densely ionizing radiation. For X-rays, wide knowledge about bi-
ological dosimetry exists, but the knowledge about densely ionizing radiation
is rather limited. The dose-effect curves that were obtained during this work
therefore provide a useful extension.
From the dose-effect curves, information on the relative biological effective-
ness (RBE) of the different C-ion energies compared to X-rays were obtained.
A precise knowledge of the RBE is most important to predict the biological
effects of heavy ion irradiation [Kraft, 1999]. The mFISH staining technique
allows identifying different aberration types, therefore the frequencies of dif-
ferent aberration types (excess acentric fragments, simple exchanges, complex
exchanges) were investigated. The corresponding RBE values for simple and
complex exchanges were calculated. The aberration spectrum was analyzed
regarding the presence of a biomarker (fingerprint) for densely ionizing radia-
tion (C-ratio: ratio of complex to simple exchanges). All this information can
help to gain a better understanding of the formation of cytogenetic damage
after exposure to densely and sparsely ionizing radiation.
At present, C-ion therapy is performed in Heidelberg, Germany, and in
Chiba and Hyogo, Japan. The Heidelberg ion therapy center (HIT) followed
after a pilot project for C-ion therapy at GSI Helmholtzzentrum fu¨r Schwer-
ionenforschung (GSI), Darmstadt, Germany. The pilot project started in
1997, mainly with the treatment of tumors in the head- and neck region. A
clinical trial with prostate-cancer patients started in 2006. The pilot project
yielded very good results [Schulz-Ertner et al., 2003, 2007a,b], which are based
on the physical and biological advantages of C-ion beams. The inverse depth-
dose profile of C-ions compared to photons allows a higher dose to the tumor,
the enhanced RBE of C-ions in the region of the physical dose maximum
potentiates the dose to radioresistant tumors [Kraft, 2000b; Kraemer et al.,
2003]. But the question was raised whether this extremely good tumor control
is followed by an enhanced risk of secondary tumor production.
For the in vivo investigations peripheral blood lymphocytes from prostate-
cancer patients treated with IMRT or C-ion boost plus IMRT were obtained
before, during and after therapy. In addition to the monitoring of the aber-
ration yields during therapy course, their persistence up to one year after
therapy was investigated. The aberration frequencies and aberration patterns
were compared for the different therapy regimens.
The prostate-cancer patients were chosen for this study for several rea-
sons. As a main purpose of this work was to study the radiation effects
on the surrounding tissue, which is represented by the blood lymphocytes,
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it was essential to choose a tumor whose radiotherapy exposes a sufficiently
large volume of normal tissue. External beam radiotherapy of prostate can-
cer unavoidably exposes a large volume of normal tissue to radiation, as the
prostate is located in the inner part of the pelvis. Another important point is
the estimation of the risk of secondary cancers, arising from irradiated stem
cells. External beam radiotherapy of prostate cancer unavoidably exposes the
bone marrow in the femur head and the pelvis to the radiation, and there-
fore prostate-cancer patients were suited for this study. Other reasons, which
played a role as well, were of practical nature. Choosing a tumor-type treated
in the GSI pilot project made it easy to obtain samples, which were taken in
Heidelberg or Darmstadt, and could be transported to the laboratory in short
time. For obtaining a blood sample one year after therapy it was advanta-
geous that most patients lived in the area and attended a follow-up care in
the Heidelberg University Hospital.
The impact of radiotherapy with different radiation qualities on the tumor
control and on possible side effects can be monitored in clinical studies in
parallel to the therapy and during a comparably short follow-up time. But
late effects of radiotherapy, including secondary cancers, occur many years
after the treatment. The comparison of the aberration frequencies between
different radiotherapy regimes can predict the relative risk of late effects. Late
effects are increasingly important, as modern radiotherapy achieves increasing
tumor control rates and longer patient survival. The results obtained in the
present study will be applicable for other tumor types as well. C-ion therapy
is increasingly used, it is for example also applied to pediatric tumors [Combs
et al., 2009], thus it is most important to achieve better information about the
risk for late effects of C-ion irradiation. In prostate-cancer patients, which are
mostly over 60 years old at the time of diagnosis, secondary cancers, occuring
typically many years after the therapy, are of minor importance compared to
other therapy-related problems (e.g. rectal bleeding [Ishikawa et al., 2006]).
The aberration analysis with mFISH provides various information including
the involvement frequencies of individual chromosomes in aberrations, thus
an analysis of the distribution of breaks in the individual chromosomes was
performed, although this was not a main goal of the study.
In the following sections of this chapter the physical, biological and medical
backgrounds relevant for this work are described. In Section 1.2 the interac-
tion mechanisms of X-rays and charged particles with matter are described, in
Section 1.3 the biological effects of ionizing radiation, with special respect to
DNA damage, DNA repair and aberration formation are given. Sections 1.4
and 1.5 provide information about prostate cancer and about external beam
radiotherapy, the latter with a focus on the radiation qualities relevant for the
work presented here, i.e. photons and C-ions.
4 Chapter 1. Introduction
1.2. Physics of ionizing radiation
The radiation qualities relevant for the application in radiotherapy can be di-
vided into two classes. Electromagnetic radiation like γ-radiation and X-rays
and particle radiation like electrons, protons, α-particles and heavy ions. Both
types of radiation were used for the work described in this thesis, namely X-
rays and C-ion beams. The interaction mechanisms of both radiation qualities
with matter are described in the following sections.
1.2.1. Interaction of X-rays with matter
X-rays interact with matter mainly via three different mechanisms: photo-
electric effect, Compton scattering and pair production. The contributions of
these three effects to the total energy deposition depend on the photon energy
and on the target material. The photoelectric effect is the dominant effect for
low photon energies. The photon transfers its energy to an atomic electron,
ejecting this electron from the atom. The kinetic energy of the emitted elec-
tron is equal to the energy of the incident photon minus the binding energy of
the electron. The Compton effect is the main mechanism of energy transfer to
the target material for intermediate energies. The incident photon transfers
a part of its energy to an atomic electron causing its liberation, while the
remainder of the original photon’s energy is emitted as a new, lower energy
photon with an emission direction different from that of the incident photon.
Pair production is the dominant process for high photon energies, it becomes
possible with photon energies exceeding 1.02 MeV. By interaction with the
electric field of a nucleus, the energy of the incident photon is converted into
an electron-positron pair. The energy of the initial photon minus the energy
necessary to produce the electron-positron pair appears as the kinetic energy
of the electron-positron pair and the recoil nucleus.
Macroscopically the intensity loss of electromagnetic radiation in matter
can be described by the absorption law
IX = I0 · e−µx (1.1)
with the initial intensity I0, the intensity Ix at the penetration depth x and
the absorption coefficient µ, which is a sum of the coefficients of the effects
described before.
For low energetic X-rays, the dose deposition in matter follows an expo-
nential decrease, as can be seen for 120 keV X-rays in Figure 1.1. For high
energetic photons the electrons are scattered mainly in forward direction,
leading to a dose increase (build-up effect) within the first few centimeters of
the material followed by an exponential decrease, as shown in Figure 1.1 for
60Co γ-rays and for 18 MeV photons.
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Figure 1.1.: Comparison of the depth-dose profiles of photons and C-ions in
water. (This figure is taken from Kraft [2000a]).
1.2.2. Interaction of charged particles with matter
In contrast to X-rays, heavy ions do not deposit most of their energy at the
beginning of their way through matter, but on the very end of their track.
Heavy ions have, also in contrast to X-rays, a well-defined range in matter
which depends on the initial energy of the particles. The peak-shaped dose-
deposition curve of heavy ions in matter is called Bragg curve, named after
the British physicist and chemist Sir William Henry Bragg (1862 - 1942), who
first described the inverse depth dose profile of heavy ions in 1904 [Brown and
Suit, 2004]. The depth-dose profiles of C-ions of different energies are shown
in Figure 1.1.
An important term describing the energy deposition of a charged particle
beam in a target material is the linear energy transfer (LET). The LET of
charged particles in a medium is defined as
LET∆ =
(
dE
dl
)
∆
(1.2)
where dl is the distance traversed by the particle and dE is the energy loss due
to collisions with electronic energy transfers less than some specified value ∆
[ICRU, 1970]. LET∞ includes all electrons and equals the energy loss of the
ion. The maximum energy transfer that is possible depends on the type and
velocity of the incident particle. In the following sections, the use of “LET”
without any subscript refers to a LET∞. Figure 1.2 shows the LET as a
function of the particle energy for different ions.
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Figure 1.2.: Linear energy transfer (LET) as a function of particle energy for
different ions. (This figure is taken from Kraft [2000a]).
Heavy ions deposit their energy in two ways: interaction with the target nu-
clei and interactions with target electrons. Nuclear stopping is the dominant
process for low projectile velocities corresponding to particle energies below
about 10 keV/u. For energies used in tumor therapy with particle beams, the
electronic stopping, i.e. the interaction of the projectile ions with the target
electrons is the main path of energy transfer to the target material (see Kraft
et al. [1992] for a review). The Bethe formula, named after Hans Albrecht
Bethe (1906 - 2005), a German-American physicist, describes the electronic
energy loss per traveled distance of swift charged particles traversing matter:
− dE
dx
= 4piN
Z2effe
4
mec2β2
· ZT ·
[
ln
(
2mec
2β2
I (1− β2)
)
− β2
]
(1.3)
with N the number of target atoms per volume, Zeff the effective nuclear
charge of the projectile, e the elementary charge, me the rest mass of the
electron, βc the velocity of the projectile, ZT the nuclear charge of the target
material and I the mean ionization potential of the target. For high energies
the projectile nuclei have lost all their electrons, Zeff = ZP , for lower energies
the effective charge of the projectile nucleus is described by the empirical
Barkas formula [Barkas, 1963]
Zeff = ZP
(
1− e−125βZ−2/3P
)
(1.4)
with the effective projectile charge Zeff , the nuclear charge of the projectile
ZP and βc the velocity of the projectile.
The absorbed dose in a target material is defined as the energy deposited
per unit mass, measured in units of Gray (1Gy = 1J/kg) [ICRU, 1970]. When
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a thin target is irradiated with a parallel particle beam, the absorbed dose is
given by
D [Gy] = 1.602 · 10−9 · dE
dx
[keV/µm] · F
[
cm−2
]
· 1
ρ
[
cm3
g
]
(1.5)
where F is the particle fluence and ρ is the density of the target material.
dE
dx
is the energy loss, which is equivalent to the LET because all electronic
energy transfer processes are taken into account.
On a microscopic scale, the ionization events caused by a projectile particle
are arranged along the particle track. Two types of ionization events can be
distinguished, ionizations caused by primary collision of the projectile particle
with target electrons, and ionizations caused by electrons that received an suf-
ficiently large energy transfer to produce further ionization events themselves
(those electrons are called δ-electrons). With decreasing particle energy the
distance between the ionization events decreases, therefore ion beams with
low energy (and high LET) are densely ionizing, while ion beams with high
energy (and low LET) are sparsely ionizing similar to X-rays. The radial
dose distribution of a particle track and the track diameter are determined by
the primary energy distribution of the electrons and their energy loss. The
radial dose distribution within a particle track D(r) is inversely proportional
to the squared radial distance i.e. D(r) ∝ 1/r2. The maximum radial range
of δ-electrons Rmax increases with the energy of the primary particle and is
described by a power law [Kiefer and Straaten, 1986] Rmax = 0.05 ·E1.7 where
Rmax is measured in µm and E is the specific energy of the ion in MeV/u.
Figure 1.3 shows simulations of ionization events in water caused by protons
and C-ions of different energies on a nanometer scale. It is visible that the
density of the ionization events increases with decreasing projectile energy,
and is higher for C-ions compared to protons. Many ionization events are
located around the center of the particle track, while some high-energetic
electrons transfer energy to the outer part of the projectile track (δ-electrons).
As described in the following section, the DNA is the sensitive target for
radiation in cells and the diameter of a DNA double stand is about 2 nm.
Comparsion of the size of the DNA molecule with the distribution of ionization
events shown in Figure 1.3 illustrates that the damage induced in a DNA
molecule will be much more complex if it is hit by a high-LET ion compared to
a low-LET particle. Even for low average doses the locally applied dose in the
track center is extremely high for high-LET particles, while other areas remain
completely without dose deposition. This high ionization density along the
track of a high-LET particle leads to different effects after exposing biological
targets to high-LET particle beams compared to X-rays or other low-LET
radiation.
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Figure 1.3.: Simulations of ionization events produced by protons and C-ions
of different energies in water along a 20 nm track segment. (Courtesy of M.
Kra¨mer.)
1.3. Biological effects of ionizing radiation
The understanding of the biological effects of the different types of ionizing
radiation is of great importance. Humans are exposed to a variety of ionizing
radiation sources including the natural background radiation, radiation for
diagnostic and therapeutic purposes, accidental or occupational exposure. In
addition, the exposure to ionizing radiation is one of the main topics for
manned space missions (e.g. Durante and Cucinotta [2008]; Durante et al.
[2007]; Schimmerling et al. [2003]; Kiefer [1999]).
1.3.1. DNA - the target for ionizing radiation
The effect of radiation on cells results mainly from the damage induced in
the deoxyribonucleic acid (DNA) molecules, which are contained in the cell
nucleus. This was shown in a study by Munro [1970], who irradiated either
cell nucleus or cytoplasm only.
The DNA, which encodes the genetic information, consists of two molecule
strands which are held together by hydrogen bonding of complimentary base
pairs and form the well-known double helix structure, which was first de-
scribed by Francis Crick and James Watson in 1953 [Watson and Crick, 1953].
Each strand is comprised of subunits, called nucleotides, which are made of
sugar, phosphate and one out of the four different bases: adenine (A), thymine
(T), cytosine (C) and guanine (G). These bases form complimentary pairs of
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A-T and C-G which are the inner part of the double helix structure. The se-
quence of bases codes the genetic information. Each human cell contains about
3 · 109 nucleotide pairs of DNA [Alberts et al., 2005]. The DNA molecules are
associated with proteins and are folded to highly organized structures. The
highest grade of chromatin condensation is achieved during metaphase, when
the chromatin condenses to form chromosomes which are visible under the
microscope. Human cells contain 46 chromosomes, 22 pairs of autosome chro-
mosomes and the sex chromosomes, XX in females and XY in males (a review
about the discovery of the number of human chromosomes is given by Harper
[2006]). The behavior of the chromosomes during cell division was first de-
scribed in 1882 by Walter Flemming, who introduced the terms “prophase”,
“metaphase” and “anaphase” [Obe and Vijayalaxmi, 2007].
During each cell cycle division, a cell undergoes several steps. A schematic
illustration of the cell cycle is shown in Figure 1.4. The division of the cycle
in four equal portions was made for clarity reasons and does not reflect the
actual duration of each phase. One cell cycle generally takes between 12 and
24 hours for most cells in cell culture, thereof the mitotic phase (M-phase)
takes typically only one hour. The cell cycle interphase consists of G1-, S- and
G2-phase. In G1-phase, biosynthetic activities take place, including the syn-
thesis of enzymes required for DNA replication. DNA synthesis takes place in
S-phase, in this phase all DNA is replicated so that each chromosome, which
consisted of one chromatid in G1-phase, consists of two sister chromatids
when S-phase is finished. In G2-phase, proteins necessary for the following
mitotic phase (M-phase) are synthesized. In the M-phase nuclear division and
cytoplasmic division take place. During nuclear division the sister chromatids
of each chromosome are divided into the two daughter nuclei. After nuclear
and cytoplasmic division, the two identical daughter cells that were created
can either start cell cycle progression once again, or they can enter a resting
phase (G0-phase). Cells can remain in the G0-phase for days, weeks or even
years [Alberts et al., 2005]. G0-phase is very common for cells that are differ-
entiated. For example blood lymphocytes, which were used in this work, are
normally in G0-phase and they can persist in this phase for several years in
the human body.
1.3.2. DNA damage induced by ionizing radiation
Ionizing radiation deposits energy in the cell nucleus either by directly ionizing
the target (DNA) molecules or by ionizing other molecules, particularly water,
since 80% of a cell is composed of water. If the ionization takes place in water
molecules, a large variety of radicals are formed where the OH radical is most
important and damages the DNA (this is called “indirect effect” [Hall, 1988]).
Radiation induces several types of DNA damage, which are of different
severity regarding their possible repair and consequently the fate of the cell.
These lesions are base damages (base loss or base modification), single strand
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Figure 1.4.: Schematic view of the cell replication cycle.
breaks, double strand breaks and DNA-DNA or DNA-protein cross-links. In
addition, several double strand and single strand breaks in close proximity
form a so-called clustered lesion. DNA double strand breaks, and especially
clustered lesions, are the most severe type of DNA damage induced by ionizing
radiation determining the fate of the damaged cell.
1.3.3. DNA repair
During cell cycle, several DNA damage checkpoints exist, which arrest the
cell cycle progression to allow repair and to prevent the transmission of DNA
damages to daughter cells [Sancar et al., 2004]. For the radiation-induced
damage, which is the topic of this thesis, the G1/S checkpoint and the G2/M
checkpoint are most relevant. The former prevents the duplication of damage
during S-phase by keeping the cell in G1-phase until the damage is repaired,
the latter prevents a cell with damaged DNA to undergo mitosis and transfer
the damage to daughter cells.
Cells can repair DNA damages via different repair pathways; their use de-
pends on the type of damage and the actual cell cycle stage. The repair
pathways are: base excision repair, mismatch repair, nucleotide excision re-
pair and double strand break repair pathways [Sancar et al., 2004; Christmann
et al., 2003]. As double strand breaks are the critical damage induced by ra-
diation, especially if they form clustered lesions, the two main pathways to
repair double strand breaks, the homologous recombination (HR) and the
non-homologous end-joining (NHEJ) are described in the following. NHEJ is
an error-prone repair pathway and is the dominant pathway in G0/G1-phase,
while HR is error-free and occurs during late S-phase and G2-phase. In HR,
the information lost in the broken double strand is retrieved from a homol-
ogous DNA double strand. In contrast, the NHEJ reconstitutes the DNA
molecule by joining the DNA ends without homology requirements and there-
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fore without ensuring sequence restoration in the break region. The NHEJ is
mainly responsible for the chromosomal exchanges observed after exposure of
cell in G0/G1 cell cycle stage (as it was done in the work presented here) to
ionizing radiation.
A third DSB repair pathway, the single strand annealing (SSA), removes
the DSB by annealing the DNA segments containing the break with a homolo-
gous segment on the same DNA molecule while excising the parts in between.
SSA is therefore associated with a loss of information, but does not lead to
exchanges between different chromosomes, and can therefore be regarded as
a transitional pathway between the error-free HR and the error-prone NHEJ.
More details about the different repair pathways can be found in several re-
views, e.g. Pfeiffer et al. [2000, 2004]; Christmann et al. [2003]; Sancar et al.
[2004]; Wyman and Kanaar [2006]; Kobayashi et al. [2008] and Sasaki [2009].
Misrepair of DNA damage contributes to therapy-induced carcinogenesis
[Allan and Travis, 2005]. Translocations are a form of transmissible aberra-
tions and are often found in cancer tissue. The first consistent chromosomal
aberration found in human cancer was the Philadelphia chromosome, which
causes chronic myeloid leukemia, it was first described in 1960 and was iden-
tified as a translocation between chromosomes 9 and 22 in 1973 [Mitelman
et al., 2007].
1.3.4. Chromosomal aberrations
As described in the previous section, the repair of DSBs, which have been in-
duced by exposure to ionizing radiation and other physical or chemical agents,
can lead to alterations in the DNA molecules which are observable as chro-
mosomal aberrations. Chromosomal aberrations are therefore a useful tool
to monitor radiation exposure [Edwards et al., 2005; International Atomic
Energy Agency, 2001].
To observe chromosomal aberrations, cells can be arrested in mitosis by
the use of colchicine [International Atomic Energy Agency, 2001]. To make
the chromosomes suitable for microscopy, the cells are exposed to a hypotonic
solution for a defined time and are afterwards fixed (usually with a combi-
nation of methanol and acetic acid) and are dropped onto microscopy glass
slides. Although chromosomes are visible without staining if a phase con-
trast microscope is used, they are generally stained before the analysis. Solid
staining with a single color, e.g. staining with Giemsa solution allows the anal-
ysis of different aberration types, such as polycentric chromosomes, acentric
fragments, ring chromosomes and chromatid-type exchanges. Other aberra-
tion types such as translocations and insertions are normally not recognizable
with Giemsa staining, unless sophisticated banding analysis is performed, e.g.
G-banding. For G-banding, the metaphases are treated with pepsin and then
stained with Giemsa solution, yielding a strong staining of A-T rich regions
and a light staining of C-G rich regions, resulting in a unique banding pattern
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of each chromosome pair. However, the analysis of chromosomal aberrations
by G-banding is very time-consuming. The development of fluorescence in situ
hybridization (FISH), which uses DNA probes labeled with fluorescence colors
that bind specifically to a pair of homologue chromosomes, made it possible
to visualize translocations and insertions without the sophisticated banding
technique. While it was first only possible to stain one or two pairs of chro-
mosomes at once, the multiplex FISH (mFISH) brought further improvement
as it allows to identify all chromosome pairs at once and is therefore suited to
identify complex chromosomal rearrangements in addition to the other aber-
ration types [Speicher et al., 1996; Kearney, 2006]. The mFISH technique
uses combinations of fluorescence colors to assign a unique artificial color to
each chromosome pair. Examples of metaphase spreads stained with Giemsa,
2-color FISH and mFISH are given in Figure 1.5. Figure 1.6 shows the differ-
ence in aberration recognition for single-color staining and mFISH. The same
aberrant metaphase is displayed in Figure 1.6 (a) in DAPI (4’,6-Diamidino-2-
phenylindol) staining which allows to detect one non-transmissible aberration,
and in Figure 1.6 (b) in mFISH staining where two transmissible aberrations
are visible in addition to the non-transmissible exchange.
(a) (b) (c)
Figure 1.5.: Examples of different chromosome staining techniques.
(a) Giemsa stained metaphase, (b) 2-color FISH stained metaphase (courtesy
C. Fournier), (c) mFISH stained metaphase (three-color display is shown).
Chromosomal aberrations are classified according to different scoring sys-
tems. They can be divided into different groups according to their com-
plexity (i.e. distinguishing terminal deletions, simple exchanges and complex
exchanges), their completeness (i.e. distinguishing complete aberrations, in-
complete rejoined aberrations and one-way aberrations [Cornforth, 2001]) and
according to their transmissibility to daughter cells. The aberration scoring
criteria and classification systems used in the present study are described in
more detail in Section 2.6. The choice of a classification system depends on
the applied staining and on the question that is to be answered. While the in-
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(a) (b)
Figure 1.6.: mFISH stained human peripheral blood lymphocyte carrying
aberrations. (a) DAPI image, which is comparable to solid staining. Only
non-transmissible aberrations are recognizable, here a dicentric chromosome
with an accompanying acentric fragment. (b) mFISH staining reveals that in
addition two transmissible exchanges are present in this cell.
vestigation of a special type of aberration (e.g. complex exchanges, insertions)
might be of interest for the identification of a possible fingerprint of densely
ionizing radiation [Testard et al., 1997; Anderson et al., 2003; George et al.,
2003b; Johannes et al., 2004], transmissible aberrations are most relevant for
the question of long-term effects of radiation exposure, as they can be passed
to daughter cells and may induce cancer [Mitelman et al., 2007].
1.3.5. Relative biological effectiveness of densely ionizing
radiation
When biological endpoints like cell inactivation or aberration formation are
investigated after cell exposure to sparsely and densely ionizing radiation, the
outcome is often different regarding the physical doses necessary to produce
the same biological effect, e.g. the induction of a defined number of aberra-
tions per cell. The relative biological effectiveness (RBE) is used to describe
the effectiveness of a test radiation compared to a reference radiation. As
reference radiation generally γ-rays or X-rays are chosen (the latter are used
in the present study). The RBE is defined as
RBE =
DX−ray
Dtest−radiation
|isoeffect (1.6)
with the X-ray dose DX−ray and the dose of the test-irradiation Dtest−radiation
that produce the same biological effect. To achieve RBE values, it is nec-
essary to generate dose-effect curves for the radiation qualities under con-
sideration. The RBE values depend on the effect level under consideration,
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Figure 1.7.: Dose-effect curves for the induction of chromosomal aberrations
in peripheral blood lymphocytes by X-rays and C-ions with an energy of
270 MeV/u, 100 MeV/u and extended Bragg peak C-ions. Aberrations were
scored on mFISH stained slides. Lines indicate how the relative biological
effectiveness (RBE) is determined. The RBE for the induction of 2 aberrations
per cell by extended Bragg peak C-ions is calculated in this example.
e.g. 10% clonogenic cell survival, 1% clonogenic cell survial, induction of 0.5
aberrations per cell. Maximum RBE values are achieved when the initial
slopes α of the dose-effect curves are compared, i.e. RBEmax = RBEα =
αtest−radiation/αx−ray. Figure 1.7 illustrates how the RBE is determined from
a set of dose-effect curves. In the example, the RBE for the induction of 2
aberrations per cell by extended Bragg peak C-ions is determined. The X-
ray dose necessary to produce 2 aberrations per cell is 2.75 Gy, the extended
Bragg peak C-ion dose necessary to produce the same effect is 1.43 Gy. Thus,
the RBE for the induction of 2 aberration per cell by extended Bragg peak
C-ions is 1.92.
RBE-LET dependencies were studied for more than half a century now, and
although the main focus was cell inactivation at the beginning [Barendsen
et al., 1960, 1963], the first RBE data for the formation of chromosomal
aberration were published only a few years later by Skarsgard et al. [1967].
RBE values depend on many factors, mainly on the LET and on the atomic
number of the projectile particles, on the biological endpoint of interest and on
the radiosensitivity of the investigated biological system, e.g. cell line or tissue
(for details see Kraft [1999]). Figure 1.8 shows the RBE-LET dependence for
the induction of one aberration per cell in lymphocytes by C-, Fe, and Xe-ions
with different energy. The RBE for induced aberrations depends for high-LET
radiation also on the sampling time. High-LET radiation induces a cell cycle
delay of heavily damaged cells leading to an underestimation of the RBE if
only one sampling time is used [Ritter et al., 2000, 2002a].
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Figure 1.8.: RBE-LET dependence for one aberration per cell induced by C-,
Fe- and Xe-ions in lymphocytes. Aberrations were scored in solid stained first
cycle metaphases after 48h incubation. (Courtesy R. Lee, unpublished data.)
The RBE is a crucial point regarding the tumor therapy with heavy ion
beams, and precise models that determine RBE values are necessary for treat-
ment planning [Kraemer et al., 2003]. A high RBE in the tumor region ensures
tumor cell inactivation, especially if a radioresistant tumor is treated. On the
other hand it is favorable to choose treatment conditions so that the RBE
in the beam entrance channel is low, especially for deep-seated tumors where
a large volume of normal tissue is located in front of the tumor, which may
contain sensitive structures such as brain stem, nerves, bone marrow or inner
organs. This requirements make C-ions suited for the therapy of deep-seated
radioresistant tumors, as they show a high RBE in the region of maximal
dose deposition, i.e. in the Bragg peak region. Heavier ions, e.g. high energy
iron ions, show an elevated RBE in the plateau region in front of the Bragg
peak while the RBE drops below 1 in the region of the Bragg peak (so called
overkill-effect) [Kraft, 1999]. The high RBE values of high-energetic iron ions
are important for space research as iron ions are found in the galactic cosmic
radiation. In contrast, light ions such as protons show an elevated RBE only
in the last micrometers of their range.
The present study determines the RBE for the induction of different types of
chromosomal aberrations in human peripheral blood lymphocytes irradiated
with C-ions of different energies. The energies were chosen such that they
cover the energy range applied in tumor therapy with C-ions.
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1.3.6. Influence of radiation quality on aberration spectrum
As described in the previous section, the biological effectiveness for the in-
duction of aberrations depends on the radiation quality. But in addition to a
change in the aberration yield, the different local dose distribution may also
be reflected in a change in the aberration spectrum. A biomarker or “fin-
gerprint” for exposure to densely ionizing radiation is suggested in several
studies. The most promising biomarker candidate is the fraction of com-
plex exchanges (C-ratio, ratio of complex to simple exchanges). An elevated
C-ratio is found after in vitro cell exposure to densely ionizing radiation com-
pared to photons in several studies applying different staining methods (e.g.
Testard et al. [1997]; Wu et al. [2003]; George et al. [2003b]; Johannes et al.
[2004]). However, other studies did not confirm these findings for in vivo expo-
sure [George et al., 2003b; Durante et al., 2004; Rithidech et al., 2007]. Other
biomarkers were proposed as well, e.g. insertions [Anderson et al., 2000],
ratios of intra-arm to inter-arm intrachanges and intra-arm intrachanges to
interchanges [Bauchinger and Schmid, 1998; Brenner et al., 2001]. Thus, from
the current state of knowledge no definite conclusion can be drawn whether
there is a suitable biomarker for densely ionizing radiation exposure in vitro
and in vivo. Increasing research in the field of densely ionizing radiation and
the application of new staining methods could help to clarify this issue.
The search for a biomarker for densely ionizing radiation is of importance
as humans are exposed to a variety of densely and sparsely ionizing radiations,
e.g. occupationally, accidentally or for medical purposes. In case an overex-
posure occurs, the dose to which an individual was exposed can be estimated
using biological dosimetry [International Atomic Energy Agency, 2001], but it
would be desirable to gain information about the radiation quality in parallel
by the use of a specific biomarker.
In the work described here, the mFISH method was applied to score aber-
rations in human peripheral blood lymphocytes exposed to X-rays and C-ions
in vitro and in vivo. In parallel to the analysis of the aberration yield, the
aberration spectrum was determined to search for possible biomarkers for the
exposure to C-ions in vitro and in vivo.
1.3.7. Chromosome territories
DNA is not randomly distributed in the cell nucleus, but occupies distinct
micrometer-scale territories during interphase (mFISH stained interphase nu-
clei give an impression of the distinct chromosome regions, as can be seen in
Figures 1.5 (c) and 2.4 (h)). A detailed review about the discovery of chromo-
some territories and the present knowledge about nuclear architecture is given
by Cremer and Cremer [2006a,b]. The territories of individual chromosomes
in the cell nucleus are believed to follow regular patterns, i.e. chromosomes
that occupy neighboring territories in one cell are expected to be neighbors
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also in other cells, at least within the same tissue and organism. If this is true,
the relative positioning of chromosomes in the interphase nucleus should be
reflected in the induced chromosomal exchanges when the cells are exposed
to ionizing radiation, i.e. neighboring chromosomes are expected to form ex-
changes more frequent than distant chromosomes. When mFISH analysis is
performed, the information about the exchange rates between individual chro-
mosomes can be obtained. To address the question of interphase positioning
of chromosomes, data about the exchange frequencies were collected for all
analyzed metaphases during the work described here.
1.4. Prostate cancer
Prostate cancer is the most frequent cancer in males, with an incidence of
about 58.000 cases per year in Germany. With a total of 230.000 cancer
incidences in males, prostate cancer therefore represents a 25 % fraction of
all cancer incidences in men in the German population (data published by
Robert Koch Institut, Berlin, Germany1). Prostate cancer occurs mainly in
elderly man. About 90% of the patients are 60 years or older at the time of
diagnosis, the mean age at time of diagnosis is about 70 years. Therefore,
albeit it is the most common cancer diagnosed in men, it is in Germany the
6th-most-common cause of death in men, and the second-most common cause
of cancer-related deaths in men after bronchial carcinoma (data published by
Statistisches Bundesamt Deutschland2). The treatment of prostate cancer
is therefore one of the main topics in cancer therapy. Several therapeutic
strategies exist for prostate cancer treatment including radiotherapy, surgery,
hormonal therapy and chemotherapy. Prostate cancer is generally a slow-
growing tumor and therapy can cure the cancer or delay its growth.
The prostate-cancer patients in the study presented here were treated with
photon IMRT or a combination of C-ion boost and IMRT. After the ther-
apeutic potential of heavy ions for locally advanced prostate cancer was in-
vestigated [Nikoghosyan et al., 2004], the clinical trial started in 2006. A
treatment plan for the IMRT and C-ion boost irradiation is shown in Figure
1.9. A homogeneous high dose in the target volume is achieved with both
radiation qualities. However, the dose decrease at the edges of the target
volume is steeper in the case of C-ion boost, leading to a better sparing of
sensitive organs close to the tumor, as can be seen in the treatment plan for
the rectum. The dose to the femur heads is comparable for both treatment
conditions. The total volume of irradiated normal tissue is much lower in
the case of C-ion boost, as only two beam ports are necessary to achieve the
high homogeneous tumor dose, while seven irradiation fields are used for the
1www.rki.de
2www.destatis.de
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Figure 1.9.: Treatment plans for prostate radiotherapy with IMRT (7 coplanar
fields, upper panel, 30 fractions, a` 2 Gy) and a C-ion boost (2 fields, lower
panel, 6 fractions, a` 3 GyE). Shown is in grayscale the computed tomogram
overlaid by the prescribed dose percentage in color. The thick contour repre-
sents the clinical target volume, the dashed contour the gross tumor volume,
and the thinner contours rectum, as well as the femoral head as organs at risk.
(Data courtesy of A. Nikoghosyan/ J. Debus, Heidelberg University Hospital.)
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IMRT. Details about external beam radiotherapy with photons and charged
particles are provided in the following section.
Possible side effects of prostate cancer treatment using external beam ra-
diotherapy are diarrhea, rectal bleeding, urinary incontinence and impotence.
Side effects occur within a few weeks after beginning of therapy and often
resolve without treatment within several months. Late effects of external
beam radiotherapy for prostate cancer include rectal/bowel, urinary and sex-
ual symptoms and a slightly higher risk of developing second solid tumors
[Brenner et al., 2000; Bostrom and Soloway, 2007; Mueller et al., 2007]. The
risk of developing secondary tumors is expected to depend on the applied
radiotherapy, as the dose-distribution in the normal tissue varies with radio-
therapy technique [Hall and Wuu, 2003; Hall, 2006].
1.5. External beam radiotherapy
Treating cancer patients is one of the main tasks in modern medicine. Cancer
is the second most common cause of death after cardiovascular diseases in the
developed countries. The first application of ionizing radiation for therapy
of malignant tissue was performed shortly after the discovery of X-rays by
W.C. Ro¨ntgen in 1895. Because their nature and their biological interaction
were not known at that time, X-rays were first used on a very empirical basis.
The first therapeutic application is reported by Prof. Freund in Vienna who
irradiated and removed a hairy mole on the forearm of a patient [Hall, 1988].
1.5.1. Fractionation
For a curative treatment of solid tumors, high doses of about 60 Gy are applied
in the target volume. These doses are fractionated, typically in 30 daily
fractions of about 2 Gy at five days per week. Fractionation allows cells in
the surrounding normal tissue, which is unavoidably exposed to some dose
during therapy, to recover. And it enables reoxygenation of hypoxic areas in
the tumor. As hypoxic cells are very radioresistant, reoxygenation of hypoxic
areas improves radiation-induced cell inactivation [Hall, 1988].
1.5.2. Photon irradiation
Photon radiotherapy is the most widely used type of external beam radiother-
apy. According to the location of the tumor, photons with different energies
are applied, as the shape of the depth-dose profile depends on the photon
energy (see Figure 1.1). For deep-seated tumors like prostate cancer pho-
tons from megavolt accelerators are used. Modern types of photon therapy
are the 3D-conformal radiotherapy and intensity modulated radiation therapy
(IMRT). In both cases the patient is irradiated from several sides, for each
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irradiation field an absorber is placed between accelerator and patient which
has a hole that shapes the beam according to the size and geometry of the
tumor. In the case of IMRT, in addition to the 3D-conformal application the
applied dose is varied within each field.
1.5.3. Proton irradiation
Tumor therapy with accelerated protons was first performed from 1954 to 1957
in Berkeley, USA. Since this time, the use of accelerated proton beams for
tumor therapy spread widely. A list of facilities using proton beams or other
charged particle beams can be found at the homepage of the “Particle Therapy
Co-Operative Group” (PTCOG)3. Proton beams show an inverted depth-dose
profile compared to photons and are therefore suited for the treatment of deep-
seated tumors. In contrast to heavier ions, protons have the disadvantage of
higher range straggling and lateral scattering. Also in contrast to heavier
ions, protons show an enhanced relative biological effectiveness restricted to
the last micrometers of range only, so that for treatment planning an overall
RBE of 1.1 is used.
Proton therapy is used for a variety of different tumor sites including
prostate cancer, which is the topic of the work presented here. The first
clinical trial using a proton boost irradiation together with X-ray treatment
for therapy of prostate cancer was published in 1979 [Shipley et al., 1979]
and good tumor control was achieved without severe side or late effects. Sev-
eral other studies followed, for a review on the role of proton therapy in the
treatment of prostate cancer see Efstathiou et al. [2009].
1.5.4. Irradiation with accelerated C-ions
Tumor therapy with ions heavier than protons was started in Berkeley, USA,
in 1957 using Helium ions. Heavier ions followed from 1975 on including
carbon, neon and argon ions [Castro et al., 1980]. Several tumor sites were
treated. Therapy with heavy ions was terminated in Berkeley in 1992; two
years later started in Chiba, Japan, tumor therapy with C-ions. In 1997
tumor therapy with C-ions began at GSI Helmholtzzentrum fu¨r Schwerionen-
forschung, Darmstadt, Germany, and in 2002 a facility in Hyogo, Japan, began
tumor therapy with C-ions. The GSI pilot project was terminated in 2008,
over 440 patients were treated at GSI. Recently, in November 2009, the first
patient was treated at the HIT ion therapy facility in Heidelberg, Germany.
Physical and biological advantages of C-ions
Carbon ions show an inverse depth-dose profile compared to photons, that
makes them suited for the treatment of deep-seated tumors (see Figure 1.1).
3http://ptcog.web.psi.ch/
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Compared to protons, which show a similar inverted depth-dose profile, Car-
bon ions show less range straggling and lateral scattering. A recently pub-
lished review by Weber and Kraft [2009] compares the properties of C-ion
and proton beams regarding their application in radiotherapy. In addition to
the physical advantages, C-ions have the biological advantage of an enhanced
relative biological effectiveness in the region of the maximal physical dose
deposition, i.e. in the Bragg maximum. This enhanced effectiveness makes
C-ions specially suited for the therapy of radioresistant deep-seated tumors.
Facilities using C-ion beams for tumor therapy
Today, three facilities worldwide use C-ion beams for tumor therapy, these
are in Heidelberg, Germany and in Hyogo and Chiba, Japan. Because of
the good results from C-ion therapy several new facilities were build and will
start operation soon, others are in planning. The HIT facility in Heidelberg,
located at the Heidelberg University Hospital started patient therapy with
C-ions recently. About 1300 patients per year will be treated at HIT. The
HIT facility uses the raster scanning technique, which was first used for C-ion
therapy at GSI and is described in the following section. Other centers will
follow in Marburg and Kiel, Germany, in Wiener Neustadt, Austria, in Pavia,
Italy and in Lanzhou, China.
Technical realization of C-ion therapy at GSI
Tumor therapy with C-ions was carried out at GSI as a pilot project from
1997 to 2008. The tumor treatment with accelerated C-ion beams at GSI used
active beam shaping. For this, the target volume is divided into small volume
elements (voxels) and each is irradiated with a pencil like beam. The range
variation is achieved with an energy variation of the accelerator. The lateral
beam movement is realized using perpendicular magnets that deflect the beam
and move it from spot to spot [Haberer et al., 1993]. This setup avoids the use
of absorbers between beam exit window and patient body, which cause range
straggling, lateral scattering and nuclear fragmentation of the initial beam.
Especially avoiding the production of neutrons in the absorber material is
important, as they can cause secondary cancer in the treated patient [Brenner
and Hall, 2008]. In addition, the active scanning system allows defining the
number of particles individually for every voxel, this ensures the achievement
of a homogeneous biological effective dose within the tumor volume. This
makes treatment planning a complex task, as the number of particles must
be assigned individually to each voxel [Kraemer et al., 2000; Kraemer and
Scholz, 2000]. GSI was the first facility that used a raster scanning system
for C-ions; a similar scanning system is used for proton therapy at the Paul
Scherrer Institute (PSI) in Switzerland. The HIT facility in Heidelberg, which
started patient therapy recently, also uses the raster scanning technique and
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active energy variation.
Nuclear fragmentation takes place whenever heavy ion beams traverse mat-
ter, and the fragmentation processes must be taken into account for tumor
treatment, especially when a deep-seated tumor is treated. The fragments
have different ranges leading to a broadening of the Bragg peak [Schardt
et al., 1996]. But the fragments also offer a unique possibility for quality
control. Stripping of one or two neutrons from the 12C-ion projectiles leads
to positron-emitting 11C-ions and 10C-ions. The photon pair that is created
by annihilation of the positron can be measured using positron emission to-
mography (PET) technique [Schardt, 2007]. The observed distribution of
annihilation processes inside the patient is compared to a calculated distribu-
tion, and if deviations are detected the treatment plan can be corrected for
the following fractions.
Clinical results of C-ion therapy
C-ion beam therapy achieved good results for the treatment of several solid
tumors. At GSI, mainly patients with tumors in the head and neck region
were treated [Schulz-Ertner et al., 2004, 2007a,b]. Patients with a variety
of tumors were treated at NIRS, Chiba, Japan, the clinical results are sum-
marized in a publication by Tsujii et al. [2007]. A recent publication by
Schulz-Ertner [2009] reviewed the clinical experience with particle therapy in
adults. This review summarized clinical outcome, mostly 5-year local control,
of the therapy of different solid tumors with protons, C-ions and other heavy
ions, sometimes in combination with photon radiotherapy. For C-ion therapy
of prostate cancer, the results obtained in Japan indicate a good tumor con-
trol with limited rectal morbidity and a good quality of life 12 months after
the treatment [Ishikawa et al., 2006; Wakatsuki et al., 2008].
1.5.5. Comparing different radiation qualities and
fractionation schemes
As described in Section 1.3.5, accelerated ions have an altered relative bio-
logical effectiveness compared to photons. Tumor therapy with accelerated
C-ions takes advantage of the high RBE in the target region. However, the
RBE and its variation over the target volume must be taken into account for
treatment planning. As the RBE is not a constant weighting factor but varies
with applied dose, treatment planning becomes a skillful task [Kraemer et al.,
2000].
To take into account the RBE when a biological target is exposed to high-
LET radiation, the physical dose (measured in Gray [Gy]) has to be replaced
by the biological equivalent dose (in Gray equivalent [GyE]) that is defined as
Dbiol = Dphys ·RBE (1.7)
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where the RBE value depends on the specific biological material exposed, the
biological endpoint of interest and the level of the biological alteration. In
addition, the RBE depends in a complex way on many physical parameters
such as particle energy, atomic number and LET. The two dose concepts,
physical dose and biological equivalent dose, are substantially different and
in case of high-LET irradiation it must be carefully determined whether the
biological equivalent dose or the physical dose applied by high-LET particle
beams is compared to a photon dose. In the study presented here, both dose
concepts are used. The physical dose is used in the in vitro studies, where it
is the intention to investigate the different biological effects of both radiation
qualities. In the patient therapy study, the biological equivalent dose is used.
Another factor that makes the comparison of therapeutically applied doses
more complex is the dose fractionation. As pointed out in Section 1.5.1, radio-
therapy is generally applied in daily fractions of 2 Gy on five days per week.
However, other fractionation schemes are used, in the study presented here
a C-ion boost irradiation with 3 GyE per fraction on 6 consecutive days is
performed. As the biological outcome depends on the dose fractionation, this
must be taken into account when total doses delivered in different fractiona-
tion schemes are compared.

2. Materials and Methods
2.1. Blood donors
2.1.1. Patients
Blood samples from patients treated with C-ions and IMRT were obtained to
analyze the aberration yield in the peripheral blood lymphocytes. Twenty-two
patients with prostate cancer entered the study. The study was approved by
the local ethic commission and all patients signed an informed consent form.
The mean age of the patients at the beginning of therapy was 66 years (ranging
from 54 to 74 years). The patients were divided in three groups according to
their treatment. Thirteen patients received C-ion boost irradiation followed
by conventional photon IMRT (referred to as C-ion + IMRT patients in the
following). Six patients with a similar planning target volume were irradiated
with photon IMRT only (called IMRT patients here). Three patients with a
larger planning target volume (PTV) which included the pelvic lymph nodes
were included in the study. These patients were solely treated with photon
IMRT as well (patients are called IMRT* here).
Table 2.1 provides details about each patient regarding applied radiother-
apy, age, tumor characterization (using TNM staging and Gleason score) and
prostate specific antigen (PSA) level at the time of diagnosis. The tumor
stage is given using the TNM staging system, which is used to characterize
the actual state of solid tumors. It describes the extent of cancer in a patient’s
body. It is a universal system applicable to all solid tumors. T describes the
size of the tumor and whether it has invaded nearby tissue, N describes the
involvement of regional lymph nodes and M describes distant metastasis. The
number behind the letter increases with increasing cancer spreading. Local
tumors were staged between T1a and T3 for the patients in this study. No
patient in this study had known cancer spreading to lymph nodes or distant
metastasis. The Gleason system is used to grade prostate cancer cells ac-
cording to the microscopic appearance of the tissue, which was obtained by
biopsy or surgery. Two Gleason grades that range from 1 to 5 are added
to obtain the Gleason score (or Gleason sum) ranging from 2 to 10. Lower
Gleason scores describe well-differentiated less aggressive tumor tissue that
closely resembles normal prostate tissue; high Gleason scores describe poorly-
differentiated more aggressive tumor tissue that does not have recognizable
glands. The Gleason score ranged from 6 to 9 in the patients of this study.
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Patient Therapy Age TNM Stage GS PSA [ng/ml]
01 C + IMRT 66 T1c N0 M0 8 14.0
02 C + IMRT 71 T3 N0 M0 9 14.9
03 IMRT* 61 T1c N0 M0 8 19.6
04 C + IMRT 70 T2b N0 M0 7 11.0
05 C + IMRT 59 T1c N0 M0 7 10.9
06 C + IMRT 66 T2a N0 M0 7 16.9
07 IMRT 73 T2c Nx Mx 7 10.1
08 C + IMRT 69 T2a N0 M0 7 13.8
09 C + IMRT 69 T2c N0 M0 8 17.2
10 C + IMRT 57 T2b N0 M0 8 12.4
11 IMRT* 73 T2 N0 M0 8 24.0
12 C + IMRT 72 T1c N0 M0 7 12.9
13 IMRT* 54 T1c N0 M0 8 5.8
14 IMRT 60 T1a N0 M0 6 18.0
15 C + IMRT 74 T2b N0 M0 8 11.0
16 IMRT 59 T1c N0 M0 6 13.0
17 C + IMRT 55 T2c N0 M0 7 10.7
18 C + IMRT 68 T1c N0 M0 7 10.8
19 C + IMRT 73 T2a N0 M0 7 11.0
20 IMRT 65 T1c N0 M0 7 10.4
21 IMRT 59 T1c Nx M0 7 4.0
22 IMRT 73 T1c Nx M0 6 7.5
Table 2.1.: Patients in this study characterized by the applied radiotherapy,
the patient’s age at the beginning of radiotherapy, the cancer staging by
TNM classification of malignant tumors, the Gleason grading system (GS)
for prostate cancer and the level of PSA in the blood serum at the time of
diagnosis.
The PSA level is the most important serum marker for prostate cancer and
is widely used for prostate cancer screening [Schroeder et al., 2009; Andriole
et al., 2009]. The upper limit of normal is in most cases chosen between 2.5–
4 ng/ml [Ito et al., 2001; Hernandez and Thompson, 2004; Schroeder et al.,
2009; Andriole et al., 2009]. However, the PSA level in apparently healthy
men increases with age [Stenman et al., 2000; Chun et al., 2007]. The level of
PSA in the blood serum ranged from 4–24 ng/ml at the time of diagnosis in
the patients of this study.
Tables 2.2 and 2.3 provide information about the irradiation of the three
patient groups. As shown in Table 2.2 the planning target volume (PTV) is
larger than the gross tumor volume (GTV) as it includes larger safety margins
and for some patients it includes the pelvic lymph nodes (the patient group
called IMRT* here). The doses applied to the GTV and PTV are given
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Patient group n GTV [cm3] PTV [cm3]
mean (range) mean (range)
C-ion + IMRT 13 64 (50-90) 119 (92-151)
IMRT 6 60 (42-79) 108 (74-174)
IMRT* 3 40 (22-70) 936 (722-1247) )
all patients 22 60 (22-90) 227 (74-1247)
Table 2.2.: Volumes of the gross tumor volume (GTV) and planning target
volume (PTV) for the three patient groups. The remarkably large PTV for
the IMRT* patient group includes the pelvic lymph nodes, in contrast to the
PTV of the two other groups.
Dose to GTV Dose to PTV
Patient group n [Gy or GyE] [Gy or GyE]
mean (range) mean (range)
C-ion + IMRT 13 78 (78-78) 60 (60-60)
IMRT 6 75.9 (74.6-76.7) 69.3 (66-70)
IMRT* 3 76 (76-76) 50.7 (50-51)
all patients 22 77.2 (74.6-78) 61 (50-70)
Table 2.3.: Radiotherapeutic doses applied to the gross tumor volume (GTV)
and planning target volume (PTV) for the three patient groups.
in Table 2.3 for the three patient groups. The patients receiving a C-ion
boost were treated with 18 GyE C-ion boost to the GTV in daily fractions
of 3 GyE on six consecutive days, followed by 60 Gy IMRT to the PTV in
daily fractions of 2 Gy on five days per week. The total dose to the GTV
was 78 GyE for this patient group. Patients treated solely with photon IMRT
(patient groups IMRT and IMRT*) received a total dose to the GTV of 74.6–
76.7 Gy in daily fractions of 2–2.24 Gy (five fractions per week). The PTV was
exposed to a total dose of 50–70 Gy delivered in daily fractions of 1.5–2.2 Gy
(five fractions per week). No patient was treated with chemotherapy before
or during the radiotherapy course. Some patients (16 of 22 patients) received
a hormonotherapy.
The C-ion boost irradiation was carried out at the SIS accelerator of the GSI
Helmholtzzentrum fu¨r Schwerionenforschung in Darmstadt using the raster
scanning technique, that is described by Haberer et al. [1993]. The initial
energy of the C-ion beam was 280–370 MeV/u. The IMRT was performed at
the Department of Radiation Oncology at the Heidelberg University Hospital.
From each patient four blood samples (about 8 ml each) during the time of
therapy and follow-up were obtained, the first one before therapy, one during,
one at the end and one one year after the end of therapy. Samples one year af-
ter therapy were taken up to now from 16 patients. Figure 2.1 shows the work
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Figure 2.1.: Workflow of the blood samples obtained from healthy volunteers
and from patients. The staining method shown in parentheses was performed
in parallel, but in the case of mFISH for selected samples only.
flow of the patients’ blood samples and samples of healthy volunteers. The
handling of the blood samples and the isolation of lymphocytes is described in
Section 2.2. The sample obtained before therapy was divided into two samples
and one was irradiated in vitro with a dose of 3 Gy X-rays to determine the
individual radiosensitivity of each patient. The in vitro irradiation procedure
with X-rays is described in Section 2.3.1.
2.1.2. Healthy volunteers
Blood samples from healthy volunteers were taken for two purposes, for com-
parison with the in vitro irradiated lymphocytes obtained from the prostate-
cancer patients before therapy and to generate dose-effect curves for irradia-
tion with X-rays and C-ions. To compare the radiosensitivity of the patients
and healthy volunteers ten blood samples from seven healthy donors (males
and females, mean age 46 years, range 27–56 years) were taken and exposed in
vitro to 3 Gy of X-rays. Additionally, several blood samples from one healthy
volunteer (female, 49 years old, non-smoker) were irradiated with X-rays and
C-ions of different energies to obtain dose-effect curves. Samples from the
same donor were used for all experiments to avoid inter-individual variations
in the radiation response. The workflow of the blood samples obtained from
healthy volunteers is shown in Figure 2.1.
2.2. Isolation of lymphocytes 29
2.2. Isolation of lymphocytes
Isolation of peripheral blood lymphocytes was performed with samples ob-
tained from prostate-cancer patients and from healthy volunteers. About
8 ml of venous blood were drawn into a Vacutainer® CPTTM cell prepara-
tion tube by venipuncture (see Figure 2.2 (a)). Blood samples from patients
which were taken at the Heidelberg University Hospital were carried to GSI
for lymphocyte isolation, the time between blood drawing and isolation of
lymphocytes was shorter than three hours. The cell preparation tubes were
centrifuged at room temperature at 1700 g (n = 48.33/s) for 20 min. After
centrifugation, the red blood cells are below the gel barrier on the bottom
of the tube. Above the gel barrier and density gradient fluid is the layer
of lymphocytes and monocytes and on top is the blood plasma (see Figure
2.2 (b)). The plasma was removed with a pipette and the layer of lym-
phocytes and monocytes was transferred to a sterile 10 ml centrifuge tube.
Sterile phosphate buffered saline solution (PBS) was added, cells were resus-
pended and centrifuged for 10 min at 390 g (n = 25/s). Afterwards, the
PBS was removed and the cells were resuspended in RPMI 1640 cell culture
medium, supplemented with 20% fetal calf serum (FCS), 2 mM L-glutamine,
100U/ml penicillin and 100 µg/ml streptomycin [Lee et al., 2005], referred to
as complete medium. For in vitro irradiation, the cells were transferred into
appropriate irradiation containers. Immediately after exposure the cells were
reseeded in a final concentration of about 0.5 · 106/ml complete medium, to
which 1% phytohemagglutinin and 15 µg/ml 5-bromo-2-deoxyuridine (BrdU)
were added. Cells were then incubated for 48 hours and 72 hours at 37,
95% relative humidity and an atmosphere of 5% CO2 in air in the dark to
avoid photolysis of BrdU.
2.3. In vitro irradiation
In vitro irradiation was carried out with peripheral blood lymphocytes of pa-
tients obtained before therapy, from a group of healthy volunteers to compare
with the patients’ results and with lymphocytes from one healthy volunteer
to achieve dose-effect curves. The isolated peripheral blood lymphocytes from
the patients and the group of healthy volunteers were exposed to a dose of
3 Gy X-rays. The isolated peripheral blood lymphocytes from one healthy
volunteer were exposed to X-rays, C-ions with energies of 270 MeV/u and
100 MeV/u and as well in an extended Bragg peak C-ions with doses from 0
to 4 Gy.
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(a) (b)
Figure 2.2.: Blood sample (about 8 ml of venous blood) in a Vacutainer® cell
preparation tube. (a) Blood sample before centrifugation, the whole blood
being above the gradient fluid and polyester gel barrier. (b) After centrifuga-
tion, the blood sample is separated in its components. The blood plasma is
on the top (yellow liquid), below are the lymphocytes and monocytes (opaque
light yellow liquid above the white gel barrier). The red blood cells are below
the gel barrier at the bottom of the glass tube.
2.3.1. X-ray irradiation
X-ray irradiation was carried out at a X-ray machine (Seifert, Ahrensberg,
Germany) operated at 250 kV and 16 mA and that included 1 mm Cu- and
1 mm Al-filtering. The dose-rate was about 1.2 Gy/min. The dose applied to
the sample was measured using a PTW-SN4 dosimeter (PTW Freiburg, Ger-
many) which was placed in a specially designed plastic holder directly below
the biological sample. The irradiation was carried out at room temperature.
Isolated peripheral blood lymphocytes were exposed to X-rays in 25 cm2 cell
culture flasks or in specially designed cell containers, which were used for the
exposure to 270 MeV/u and 100 MeV/u C-ions (see Section 2.3.2).
2.3.2. C-ion irradiation
Samples from one healthy donor (female, non-smoker) were irradiated with
different doses of accelerated C-ions to generate dose-effect curves for the in-
duction of chromosomal aberrations. These experiments were carried out with
three different C-ion energies. The irradiation was performed at the heavy ion
synchrotron SIS at GSI, Darmstadt, Germany, using the intensity controlled
raster scanning technique and active beam energy variation [Haberer et al.,
1993]. The irradiation facility was the same as for the treatment of tumor
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Energy LET at sample position
270 MeV/u 14 keV/µm
100 MeV/u 29 keV/µm
Extended Bragg peak 60–85 keV/µm
Table 2.4.: Energies and LET values of the C-ion beams used for in vitro
irradiation of the isolated peripheral blood lymphocytes.
Beam energy Dose Fluence Particles/nucleus
270 MeV/u 0.5 Gy 2.22 · 107/cm2 5.55
270 MeV/u 1 Gy 4.44 · 107/cm2 11.1
270 MeV/u 2 Gy 8.88 · 107/cm2 22.2
270 MeV/u 4 Gy 1.77 · 108/cm2 44.4
100 MeV/u 1 Gy 2.14 · 107/cm2 5.36
100 MeV/u 2 Gy 4.29 · 107/cm2 10.7
100 MeV/u 4 Gy 8.57 · 107/cm2 21.4
Ext. Bragg peak 1 Gy 8.61 · 106/cm2 2.15
Ext. Bragg peak 2 Gy 1.72 · 107/cm2 4.30
Table 2.5.: C-ion doses and corresponding particle fluences applied for in vitro
irradiation of peripheral blood lymphocytes. The particle traversals per cell
nucleus were calculated assuming a cell nucleus area of 25µm2 [Anderson
et al., 2000]. Ext = extended.
patients with C-ions.
Cells were irradiated with monoenergetic 270 MeV/u C-ions, monoenergetic
100 MeV/u C-ions and 25 mm extended Bragg peak C-ions. The correspond-
ing linear energy transfer (LET) values are given in Table 2.4.
For the irradiation with monoenergetic C-ions the cell suspension was loaded
into specially designed polyethylene holders with a 2 mm thick well for the cell
suspension (about 5 ml cell suspension per well) and 1 mm plastic between
the cells and the radiation source [Lee et al., 2005; Ritter et al., 2002a]. For
irradiation with the extended Bragg peak C-ions the cell suspension was filled
in 5 ml plastic centrifuge tubes which were placed in a plastic block with cav-
ities for the centrifuge tubes [Nasonova and Ritter, 2004]. All irradiations
were carried out at room temperature.
Table 2.5 shows details about the in vitro irradiation. Cell samples irradi-
ated with 270 MeV/u C-ions and 100 MeV/u C-ions were exposed to doses up
to 4 Gy and samples exposed to extended Bragg peak C-ions received doses up
to 2 Gy. The corresponding particle fluences were calculated using Equation
1.5, and the particle traversals per cell nucleus were derived assuming a cell
nucleus area of 25 µm2 [Anderson et al., 2000].
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2.4. Cell fixation and preparation of metaphase
spreads
Cells were arrested in mitosis by adding colcemid (20µl/ml medium, stock
solution 10µg/ml) 3 hours prior to cell fixation. Colcemid inhibits the for-
mation of the spindle fibers which separate the chromatids during mitosis
and therefore leads to an accumulation of cells in mitosis. Then, metaphase
spreads were prepared according to standard protocols [International Atomic
Energy Agency, 2001]. For this the cell suspension was centrifuged for 6 min
at 200 g (n = 16.6/s), the medium was poured away and the cell pellet was
resuspended in the remaining medium (about 100 - 200 µl). Hypotonic KCl
solution (0.075 M) preheated to 37  was added carefully. After 8 min in
the hypotonic solution the cells were centrifuged again for 8 min at 290 g
(n = 20/s). The supernatant was removed and the pellet was resuspended. A
freshly prepared fixation solution made of methanol and acetic acid (3:1) was
added. After 30 min at room temperature the suspension was centrifuged, the
supernatant was removed and the pellet was resuspended in methanol/acetic
acid. After renewed centrifugation the cells were resuspended in an appro-
priate volume of methanol/acetic acid fixation solution for the preparation of
chromosome spreads. The chromosome spreads were prepared by dropping
about 20 µl of cell suspension on wet microscope slides. The quality of the
spreading and the appropriate cell density in the dropping suspension were ex-
amined under a phase contrast microscope. Slides were left overnight at room
temperature to assure complete drying. Afterwards, slides were stained using
FPG technique or were frozen at -20 for storage until mFISH hybridization.
2.5. Staining of metaphase spreads
The microscopy slides with the metaphase spreads were stained using fluores-
cence plus Giemsa (FPG) staining or multiplex fluorescence in situ hybridiza-
tion (mFISH).
2.5.1. Fluorescence plus Giemsa staining
FPG staining enables to differentiate between first, second and later cell cycle
after addition of 5-bromo-2-deoxyuridine (BrdU) to the cell culture. BrdU is
an analogue of thymidine, which is incorporated in the DNA during replica-
tion in the S-phase. The procedure of the FPG staining was first described
by Perry and Wolff [1974] and was used here with minor modifications [Rit-
ter et al., 1996]. The microscope slides were incubated in 5µg/ml Hoechst
33258 in ultrapure water for 1 h at room temperature in the dark, washed
and air-dried. Afterwards, a buffer solution (19.45 ml Na2HPO4 (0.2 M) +
0.55 ml citric acid (0.1 M)) was dropped on each slide which was then covered
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(a) (b) (c)
Figure 2.3.: Examples of FPG-stained metaphases. (a) First cycle, (b) second
cycle and (c) third cycle metaphase.
with a cover glass. The samples were irradiated for 1 h with a low-pressure
UV lamp (λ= 360 nm). Next, the slides were incubated in 2xSSC (saline-
sodium citrate) buffer for 30 min at 55, washed in ultrapure water, air-dried
and stored overnight. Finally, the microscope slides were stained with 5 %
Giemsa solution in phosphate buffer (one part 0.067 M Na2HPO4 and one
part 0.067 M KH2PO4) for 10 min, washed, dried overnight and embedded in
Eukitt. Examples of metaphases stained with FPG-technique are shown in
Figure 2.3.
2.5.2. Multiplex fluorescence in situ hybridization
Multiplex fluorescence in situ hybridization (mFISH) analysis was performed
to yield detailed information about radiation-induced chromosomal aberra-
tions in peripheral blood lymphocytes. For the mFISH analysis, slides were
hybridized using the 24XCyte mFISH kit (Metasystems, Altlussheim, Ger-
many) according to the protocol recommended by the manufacturer with mi-
nor modifications. The slides were pretreated with a pepsin solution (250 µl
0.2% pepsin stock solution in 50 ml 0.01 N HCl at 37 for one min) to digest
remaining cytoplasmic proteins. After washing in PBS, the slides were incu-
bated in 2xSSC at 70 for 30 min, followed by denaturation in 0.07 N NaOH
for 1 min, washing and dehydration in ethanol. An appropriate volume (7µl
for a 18x18 mm cover slip) of 24XCyte DNA probe was denatured meanwhile
by incubating for 5 min at 75 and 30 min at 37. The denatured probe was
then pipetted on the prepared microscope slide and covered with a glass cover
slip (18x18 mm). The slide was incubated in a humidified chamber at 37
for three days. Afterwards, the remaining hybridization probe was washed
off and the detection of the biotin-labeled probe was performed according to
the manufacturer’s protocol. Finally, all DNA material was counterstained
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Fluorochrome Excitation maximum Emission maximum
DAPI 345 nm 455 nm
DEAC 426 nm 480 nm
FITC 495 nm 521 nm
SpO 559 nm 588 nm
TR 595 nm 651 nm
Cy5 649 nm 670 nm
Table 2.6.: Excitation and emission wavelengths of the fluorochromes used in
the 24XCyte mFISH probe kit (Metasystems). The fluorochromes are 4’,6-
Diamidino-2-phenylindol (DAPI), 7-Diethylaminocoumarin-3-carboxylic acid
(DEAC), Fluorescein (FITC), Spectrum OrangeTM (SpO), Texas Red® (TR)
and CyTM5 (Cy5).
using 4’,6-Diamidino-2-phenylindol (DAPI) and the slide was covered with
a glass cover slip. The chromosome spreads were analyzed using an Olym-
pus BX61 microscope (Olympus, Tokyo, Japan) equipped with six-position
slider holding filter sets specific for the applied fluorochromes. The used
fluorochromes are Fluorescein (FITC), 7-Diethylaminocoumarin-3-carboxylic
acid (DEAC), Spectrum OrangeTM (SpO), Texas Red® (TR) CyTM5 (Cy5)
and 4’,6-Diamidino-2-phenylindol (DAPI). The excitation and emission wave-
lengths of the applied fluorochromes are listed in Table 2.6. Images of the
metaphases were captured with a charge coupled device camera and kary-
otypes were constructed using the Isis/mFISH software (Metasystems).
When FPG analysis revealed that the fraction of first mitosis (M1) was
less than 90%, the slide was destained and a FPG staining was performed
to exclude second or third cycle mitoses. For FPG staining after mFISH,
the DAPI was washed off and the FPG staining protocol was applied (see
Section 2.5.1 for details). The last step of the FPG protocol, i.e. the staining
with Giemsa solution, was substituted by DAPI staining. Afterwards the
metaphases were relocated, examined and only first division cells were used
for the analysis.
2.6. Scoring of chromosomal aberrations
For the analysis of patients’ samples obtained before therapy the scoring of
dicentrics on FPG stained slides was used. mFISH analysis of these samples
was carried out in parallel, but only for selected patients. The samples from
patients obtained during, at the end of and one year after therapy were an-
alyzed with mFISH for all patients, as well as the samples for the in vitro
dose-response curves. FPG analysis of samples obtained from the patients
during and after therapy was performed in parallel.
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2.6.1. Aberration scoring on FPG stained slides
FPG stained slides were analyzed regarding the cell cylce number after ir-
radiation as described in Ritter et al. [1996] to identify first (M1) and sec-
ond or later metaphases. Examples of FPG stained metaphase are shown
in Figure 2.3. Aberration analysis was restricted to M1 cells. For patients’
samples obtained during and after radiotherapy, aberrations in 200 M1 cells
were analyzed and for in vitro irradiated samples in at least 100 M1 cells. For
the aberration analysis, the scoring of dicentrics was chosen, as described by
the International Atomic Energy Agency [2001]. Aberration scoring on FPG
stained slides was carried out by Dr. Elena Nasonova.
2.6.2. Aberration scoring on mFISH stained slides
Analysis of mFISH stained metaphases was performed in at least 100 cells
per sample. An example of the six individual images captured from each
metaphase is given in Figure 2.4 (a) to (f). These six images are stored
as an image stack and processed together. The background is subtracted
and the chromosomes are separated automatically or by hand depending on
the quality of the metaphase spread. After processing, the chromosomes are
sorted in a karyogramm. An artificial color is assigned to each combination of
fluorescent colors and these artificial colored chromosomes is displayed in the
karyogramm. An example of a metaphase spread in artificial colors is given
in Figure 2.4 (h), an example of a karyogramm in artificial colors is given in
Figure 2.5 (a). In the karyogramm display, small colored circles and squares
under each chromosome pair indicate the artificial color and the fluorochrome
color(s) that characterize the specific chromosome.
To check each chromosome for the presence of chromosomal aberrations, a
single color gallery showing the artificial color, the five specific fluorescence
colors, an intensity profile of these five specific fluorescence colors along the
chromosome axis and an inverted black and white image of the DAPI stain-
ing is used. Changes in the color spectrum within one chromosome show the
exchange of DNA material between heterologous chromosomes. The origin of
the inserted or exchanged chromosome part is determined by its specific fluo-
rescent color signal(s). In most cases an exchange is also visible by a change
in the artificial color assigned to the chromosome, but as small exchanges do
not always result in a changing artificial color, the single color gallery is used
for the analysis. The chromosome structure is investigated using the inverted
DAPI image to determine the presence or absence of centromeres. Ring chro-
mosomes are also identified on the basis of the DAPI image. Examples of the
single color galleries are given in Figure 2.5 (b) to (d) for different chromo-
somes. Figure 2.6 (a) shows a karyotype carrying a dicentric chromosome and
an acentric fragment. Figures 2.6 (b) and (c) show the single color galleries
for both aberrant chromosomes, from the specific colors visible follows that
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 2.4.: Capture process of the mFISH images. This example shows one
metaphase spread and three interphase nuclei. Panel (a) displays the DAPI
color channel, Figures (b) to (f) show the FITC, SpO, TR, Cy5 and DEAC
color channels. Panels (g) gives a three-color image composed of the DAPI,
SpO and Cy5 images. The artificial color image is displayed in Panel (h).
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(a)
(b)
(c)
(d)
Figure 2.5.: Analysis of a mFISH stained metaphase. Panel (a) shows a normal
human male karyotype; all chromosomes are displayed in artificial colors.
Colored dots and squares in the karyogramm show the artificial color and the
specific fluorochromes for each pair of homologue chromosomes. To check for
aberrations, each chromosome is investigated using the single color gallery
display, which is shown in Panels (b) to (d) for chromosome 1, 10 and 18.
The single color gallery shows (from left to right) the chromosome in artificial
colors, the five specific fluorochrome images, an intensity profile for the five
specific fluorochromes and an inverted DAPI image.
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(a)
(b)
(c)
Figure 2.6.: mFISH stained female human metaphase with an aberration.
Panel (a) shows the karyotype which displays a dicentric chromosome with an
acentric fragment, panels (b) and (c) show the single color galleries for the two
aberrant chromosomes. The changes of fluorochrome signals in the individual
color channels and the intensity profile for these colors clearly indicate that
there is a reciprocal exchange between chromosomes 4 and 7. Analysis of
the inverted DAPI images reveals that it is a dicentric chromosome and an
acentric fragment.
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the dicentric chromosome and acentric chromosome involve chromosomes 4
and 7.
Intrachanges within one chromosome and exchanges between homologue
chromosomes are only detectable on the basis of a changed length or shape
of the chromosomes, but not on the basis of the characteristic color profile,
as homologue chromosomes are painted with the same color pattern. In the
case that an intrachange or exchange between homologue chromosomes was
detected it was recorded.
2.6.3. mPAINT nomenclature
Aberrations observed using mFISH were recorded using the mPAINT descrip-
tors [Cornforth, 2001; Loucas and Cornforth, 2001], which are an enhancement
of the PAINT system (Protocol for Aberration Identification and Nomencla-
ture Terminology) [Tucker et al., 1995] that is used for 1–3-color FISH. The
mPAINT system describes the observed chromosomal aberrations by naming
the chromosomes involved and indicating the position of the centromeres by an
apostrophe following the chromosome number. Connections between chromo-
some parts are described by linking the chromosome numbers with a “-”sign,
different aberrations are separated using a semicolon. Truncated chromosome
are indicating by a “T”, ring chromosomes by a “R”. The aberration dis-
played in Figure 2.6 is written as (4’-7’)(7-4) in mPAINT descriptors. Figure
2.7 shows examples of artificial color images of aberrations observed in this
study. Figures 2.7 (a) - (g) show a truncated chromosome with linear acen-
tric fragment, a dicentric chromosome with acentric fragment, a reciprocal
translocation, a centric ring with acentric fragment, two complex exchanges
that resulted from three or four breaks in three chromosomes and one inser-
tion. The mPAINT descriptors for these aberrations are (T2’)(2); (7’-9’)(9-7);
(4’-9)(9’-4); (R6’)(6); (3-1’)(1-X’)(X-3’); (5-2’-4)(2)(5’-4’); and (5’-9-5)(T5’).
2.6.4. Analysis of chromosomal aberrations
As mFISH allows a full analysis of chromosomal interchanges, many differ-
ent aberrations can be distinguished and these aberrations can be grouped
using different criteria. In this work, aberrations were grouped according to
their complexity (excess acentric fragments, simple exchanges and complex ex-
changes), their transmissibility (transmissible or non-transmissible) and their
completeness (complete, incomplete, one-way exchanges). In addition, the
fraction of aberrant cells and the distribution of aberrations and breaks in the
cells were determined.
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(a) (b) (c) (d)
(e) (f) (g)
Figure 2.7.: Examples of chromosomal aberrations observed using mFISH
analysis. The artificial color images of the aberrant chromosomes are shown.
(a) truncated chromosome with acentric fragment, mPAINT (T2’)(2); (b) di-
centric chromosome with acentric fragment, mPAINT (7’-9’)(9-7); (c) recip-
rocal translocation, mPAINT (4’-9)(9’-4); (d) centric ring with acentric frag-
ment, mPAINT (R6’)(6); (e) complex exchanges that resulted from three in
three chromosomes, mPAINT (3-1’)(1-X’)(X-3’); (f) complex exchanges that
resulted from four breaks in three chromosomes, mPAINT (5-2’-4)(2)(5’-4’);
(g) insertion, i.e. complex aberration resulting from three breaks in two chro-
mosomes, mPAINT (5’-9-5)(T5’).
Excess acentric fragments
Excess acentric fragments include terminal deletions and interstitial deletions,
as it is not possible to distinguish reliably between linear and circular frag-
ments with mFISH staining. An example of a terminal deletion is shown in
Figure 2.7 (a). Depending on the condensation of the chromosomes and the
length of the fragment sometimes the difference in chromosome length is not
visible and only the excess fragment is observed. It is also possible that a
truncated chromosome is observed without an acentric fragment accompa-
nying it, because small fragments can be lost during image processing due
to their weak DAPI staining signal. The group of excess acentric fragments
therefore includes three types of aberrations: truncated chromosomes with
acentric fragments, lone truncated chromosomes and lone acentric fragments.
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Simple exchanges
Simple exchanges are aberrations resulting from two double-strand breaks.
The most frequent simple exchanges are reciprocal translocations and di-
centrics with accompanying acentric fragments. Both aberration types are
the result of two double-strand breaks in two chromosomes. Examples of a
dicentric with acentric fragment and a reciprocal translocation are given in
Figure 2.7 (b) and (c). Centric rings are less frequent; they result from two
breaks in both arms of one chromosome. An example of a centric ring with
accompanying linear acentric fragment is shown in Figure 2.7 (d). Pericentric
inversions, i.e. breaks in both arms of one chromosome and inversion of the
centromeric part, are rarely observed with mFISH, as they are detectable only
if they result in a visible change of the centromere position in the chromosome,
e.g. if chromosome 1, which is normally metacentric, displays a centromere
close to the telomere region.
Complex exchanges
Complex aberrations are defined as aberrations resulting from at least three
breaks in at least two chromosomes [Savage and Simpson, 1994]. They can
be characterized by the use of the CAB (chromosomes/arms/breaks) system,
which was introduced by Savage and Simpson [1994]. The CAB system gives
the number of chromosomes involved in the aberration, the number of chro-
mosome arms in which a break occurred and the total number of breaks that
were necessary to produce the observed aberration. Examples of complex
aberrations are given in Figure 2.7 (e) to (g). Figure 2.7 (e) shows an aber-
ration with a CAB of (3/3/3), Figure 2.7 (f) shows an exchange with a CAB
of (3/4/4). Figure 2.7 (g) shows an insertion, which is defined as a complex
aberration with a CAB of (2/2/3).
Complete, incomplete and one-way exchanges
The system to classify aberrations in three groups according to their complete-
ness was introduced by Cornforth [2001]. Complete exchanges are defined as
exchanges which have all parts of the chromosomes visible and all “open DNA
ends” induced by the initial breaks repaired. One-way exchanges are char-
acterized by a missing part, e.g. there is a dicentric chromosome but the
accompanying fragment is only displaying the color of one of both involved
chromosomes. The missing part is assumed to be present but to small to be
seen with the method applied. Incomplete exchanges are characterized by
the presence of “open ends” i.e. there are unrejoined parts in the aberration.
An example is a dicentric chromosome accompanied by two separate acentric
fragments displaying only one of the two chromosome colors each.
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Transmissible aberrations
Aberrations were subdivided according to their transmissibility to daughter
cells. Specifically, reciprocal translocations were classified as transmissible
and dicentrics, rings and acentric fragments as non-transmissible. Complex
aberrations were classified as non-transmissible if they carried either a poly-
centric or an acentric part or a ring, or transmissible if neither of those.
Distribution of aberrations and breaks
The number of aberrations per cell was recorded for each analyzed metaphase.
The resulting distribution of aberrations in the cell population was determined
and compared to a Poisson and Neyman type A distribution.
After exposure to sparsely ionizing radiation like X-rays, where the dose-
distribution is homogeneous on a microscopic scale, the distribution of aber-
rations in the cells is described by a Poisson distribution
P (k) =
ake−a
k!
(2.1)
with the expectation value a being the average number of aberrations per cell
in the population. In contrast to X-rays, the microscopic dose distribution
of densely ionizing radiation is inhomogeneous, with high local doses along
the particle track (see Figure 1.3). To describe the distribution of aberra-
tions in the cells induced by high-LET radiation, two independent variables
are used, the number of particle tracks per cell and the number of aberrations
induced by one particle traversal, both parameters are assumed to follow Pois-
son statistics [Virsik and Harder, 1981; Gudowska-Nowak et al., 2007]. With
the mean number of particle traversals per cell nucleus λ, the distribution of
particle tracks per cell nucleus is given by
Pλ(n) =
λne−λ
n!
(2.2)
. The number of aberrations induced by n particle traversals is then described
by
Pnµ(m) =
(nµ)me−nµ
m!
(2.3)
with µ describing the mean number of aberrations induced by one particle
traversal. The distribution of aberrations in the cells induced by densely
ionizing radiation can then be described by a compound Poisson distribution
P (k) =
∞∑
n=0
Pnµ(m)Pλ(n) =
∞∑
n=0
(nµ)me−nµ
m!
λne−λ
n!
=
µke−λ
k!
∞∑
n=0
nk
n!
(e−µλ)n
(2.4)
which is known as a Neyman type A distribution [Neyman, 1939]. Both
distribution types, the Poisson and the Neyman type A distribution were used
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in work presented here to describe the observed distribution of aberrations in
the cells.
In addition, the total number of breaks per cell was calculated by summing
up the number of breaks that lead to all visible aberrations in each cell. As
the analysis was performed on metaphase cells 48 h after in vitro cultivation,
the term “breaks per cell” does not refer to initially induced breaks, but to the
breaks observed as aberrations after 48 h incubation, i.e. the breaks that were
misrepaired leading to chromosomal exchanges and the unrepaired breaks that
lead to terminal deletions.
2.7. Individual chromosomes
2.7.1. Involvement of individual chromosomes in
aberrations
The involvement of individual chromosomes in aberrations was investigated.
For this the number of breaks observed in each pair of homologue chromo-
somes was recorded and then plotted versus chromosome number and gene
density. The number of genes on the individual chromosome and the length
of the chromosome were taken from the homepage of the Ensembl project1
and are given in Table A.1. The distribution of breakpoints in individual
chromosomes was compared to two models, the length model, that assumes
that the breakpoints observed on the basis of chromosomal aberrations are
distributed according to the chromosome length, i.e. the DNA content f , and
the surface model, which assumes that the breakpoints observed in chromo-
somal aberrations are distributed according to the surface of a chromosome
territory in the interphase cell, i.e. according to f 2/3 [Cremer et al., 1996].
2.7.2. Exchanges between chromosomes - statistics for
chromosome interphase positioning SCHIP
Chromosomes are believed to be located in distinct areas within the interphase
cell nucleus, as described in Section 1.3.7. Chromosomal interchanges due to
misrepair during the double-strand break repair process should then be more
frequent between chromosomes located close to each other. Reversely, the
observation of excess exchange rates for certain chromosome pairs can be
regarded as a hint that theses chromosomes are located close to each other in
the interphase nucleus.
For the analysis of exchange rates between chromosomes, a table was cre-
ated with 22 rows and 22 columns, one for each pair of homologue chromo-
somes. All mFISH analyzed metaphases were analyzed regarding the observed
1http://www.ensembl.org/Homo sapiens/Location/Genome
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color changes, i.e. the interchanges between chromosomes. Each metaphase
displaying at least one color change between chromosomes i and j increased
in the table the value of the cell (i, j) by 1. The resulting table shows a tri-
angular matrix with entries f(i, j) that give the number of cells in which an
interchange between chromosomes i and j was observed.
If a random participation of the chromosomes is assumed, the pairwise
exchange yields can be written as products of single chromosome participation
factors f(i, j) = g(i)g(j). Deviations from this random model are a hint for
the presence of chromosomal territories in the interphase nucleus. For the
analysis of the table the software SCHIP (statistics for chromosome interphase
positioning based on interchange data) was used, which is available on the
Internet2 and is described in publications by Cornforth et al. [2002]; Arsuaga
et al. [2004]; Vives et al. [2005].
The table with the f(i, j) values was uploaded to the SCHIP homepage.
Candidate clusters that were to be tested in the data set were chosen from a
set of reported clusters, or own candidate clusters were used. The first part
of the output of the software is a table that shows the input data (pairwise
chromosome yields) denoted by f(i, j) in the upper left part of the table, the
normalized single chromosome participation factors g(i) along the diagonal
of the table and the deviations from the expected values assuming a random
model ∆(i, j) in the lower right part. The second part of the output is a list
of p-values for the tested candidate clusters. For the comparison with the
data obtained during the work presented here, tables with exchange yields
provided on the SCHIP homepage were used, mainly the data set that was
published by Arsuaga et al. [2004].
A set of chromosomes which are known to be located in close proximity to
each other in the cell nucleus are the acrocentric chromosomes (i.e. chromo-
somes number 13, 14, 15, 21, and 22). Those chromosomes encode ribosomal
genes on their short p-arms and are known to be located at the nucleoli in the
interphase nucleus [Krystosek, 1998; Sullivan et al., 2001; Parada and Misteli,
2002; Kalmarova et al., 2007]. This chromosome cluster was used to test the
method applied here using the SCHIP software to search for clusters.
2.8. Error propagation and statistical tests
2.8.1. Errors and error propagation
For stochastic events like aberrations induced by radiation the uncertainty of
the counted number is estimated assuming Poisson statistics
∆x =
√
x
N
(2.5)
2http://cramer.stat.ub.es/schip/
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where x is the counted number of events, e.g. simple or complex exchanges,
and N is the total number of analyzed cells.
For the fraction of aberrant cells, the error bars were calculated assuming
a binomial distribution
∆
(
a
n
)
=
√√√√ an · (1− an)
n
(2.6)
with a the number of aberrant cells and n the number of analyzed cells.
The errors of fractions such as the RBE values were calculated using error
propagation
∆RBE
RBE
=
√√√√(∆DX−ray
DX−ray
)2
+
(
∆DC−ion
DC−ion
)2
(2.7)
2.8.2. Chi-square test
The χ2-test was applied to compare the observed distribution of breakpoints
in the individual chromosomes to the expected distributions according to the
chromosome length and chromosome surface model.
χ2 =
∑ (O − E)2
E
(2.8)
where E is the expected value and O the observed value for each chromosome
pair. To test for significance, a χ2 distribution table was used [Bailey, 1995].
A p-value of 0.05 was used for the significance tests based on χ2.
2.8.3. Two-sample t-test
The two-sample t-test was used to test the patient group data for significant
differences. For two sample sets 1 and 2 the two-sample t is calculated as
t =
x1 − x2
s ·
√
1
n1
+ 1
n2
(2.9)
where x1 and x2 are the mean values of the sample sets 1 and 2, n1 and n2
the sample sizes of both groups and s is an estimate of the standard deviation
based on both samples. s is calculated as
s =
√√√√∑x12 − (∑x1)2n1 +∑x22 − (
∑
x2)2
n2
n1 + n2 − 2 (2.10)
. The t-value is then compared to a Student’s t-distribution table, e.g. Bailey
[1995]. A p-value of 0.05 was used for the significance tests.
For comparison of different patient groups two-tailed tests were applied.
When comparing the aberration yield one year after therapy with the yield
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at the end of therapy a one-tailed test was applied, as it can be assumed that
the aberration yield decreases or stays unchanged in the year after therapy
but does not increase any further.
2.8.4. Fisher’s exact test
Fisher’s exact test was used on the number of aberrant and non-aberrant cells
at the end of therapy and one year after therapy in each individual patient
from whom both samples were obtained. To calculate the p-value, a 2x2-table
was created:
number of number of
aberrant cells non-aberrant cells
end of therapy a b
1 year after therapy c d
The p-value is then calculated via
p =
(a+ b)! · (c+ d)! · (a+ c)! · (b+ d)!
n! · a! · b! · c! · d! (2.11)
with n the sum of all entries in the table. As mentioned above, for the com-
parison of aberration data obtained at the end of therapy with data obtained
one year after therapy a one-sided test was used.
3. Results
3.1. In vitro experiments
In vitro experiments were carried out to investigate the effects of X-rays and
C-ions of different energies on the aberration yield and aberration pattern
induced in human peripheral blood lymphocytes. In addition, the resulting
dose-effect curves were used for comparison with the data obtained in vivo in
the peripheral blood lymphocytes of prostate-cancer patients irradiated with
C-ion boost plus IMRT or only IMRT, which are described in Section 3.2.
3.1.1. Fraction of aberrant cells and aberrations per cell
The fraction of cells carrying at least one chromosomal aberration (excess
acentric fragment, simple or complex exchange) was investigated on mFISH
stained slides. In parallel to the mFISH analysis a FPG staining was per-
formed to determine the fraction of M1 cells, and if it was found that less
than 90% of the mitotic cells were in M1 a modified FPG protocol was applied
to the mFISH stained sample to exclude cells in second or third metaphase
from the analysis (see Section 2.5.2). The lymphocytes were irradiated in
vitro with different doses of X-rays and accelerated C-ions. The percentage
of aberrant cells is displayed in Figure 3.1. The fraction of aberrant cells
increases with dose and approaches 100% for high doses. The increase with
dose is steeper for low-energetic C-ions (extended Bragg peak and 100 MeV/u)
than for high-energetic C-ions (270 MeV/u) and X-rays.
The mean number of aberrations per cell was determined for each radiation
quality and dose. The resulting dose-effect curves are given in Figure 3.2 for
irradiation with X-rays, 270 MeV/u, 100 MeV/u and extended Bragg peak
C-ions. All types of chromosomal aberrations observed using mFISH analysis
were included. The yield of aberrations per cell increases with dose, the slope
is steeper for densely ionizing radiation (C-ions with an energy of 100 MeV/u
and extended Bragg peak C-ions) compared to sparsely ionizing radiation
(C-ions with an energy of 270 MeV/u and X-rays). The increase follows a
linear-quadratic pattern in the case of exposure to X-rays and 270 MeV/u
C-ions and shows a linear behavior in the case of exposure to C-ions with an
energy of 100 MeV/u and extended Bragg peak C-ions.
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Figure 3.1.: Percentage of aberrant peripheral blood lymphocyte metaphases
after exposure to different doses of X-rays and C-ions with different energies.
Aberration analysis was performed on mFISH stained M1 metaphases after
48 h incubation. Lines are guides for the eye. Error bars are too small to be
visible.
Figure 3.2.: Dose-effect curves for the mean number of aberrations per cell
induced by doses of 0–4 Gy X-rays and C-ions with three different energies.
The dose-effect curves of X-rays and 270 MeV/u C-ions were fitted using a
linear-quadratic function, the dose-effect curves of 100 MeV/u and extended
Bragg peak C-ions were fitted with a linear function. Erro
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3.1.2. Simple and complex exchanges
To investigate differences in the aberration spectrum, the yields of simple ex-
changes, i.e. exchanges resulting from two chromosome breaks, and complex
exchanges, i.e. exchanges involving three or more breaks in at least two chro-
mosomes [Savage and Simpson, 1994], were analyzed separately. The resulting
dose-effect curves for the induction of simple and complex chromosomal ex-
changes are displayed in Figures 3.3 (a) and (b). The number of exchanges
per cell increases with increasing dose. The induction of simple exchanges fol-
lows a linear pattern in the investigated range of doses and LET values. The
induction of complex exchanges follows a linear-quadratic pattern for the ir-
radiation with X-rays and C-ions with energies of 270 MeV/u and 100 MeV/u.
The induction of complex exchanges by extended Bragg peak C-ions was fit-
ted by a linear function in the investigated dose range, however as only two
doses (1 and 2 Gy) were used for this radiation quality extrapolation to higher
doses would be associated with a high degree of uncertainty.
3.1.3. Relative biological effectiveness
From the dose-effect curves the RBE was determined for the induction of
total aberrations, simple and complex exchanges as described in Section 1.3.5.
Table 3.1 lists the RBE values for the induction of 0.5, 1 and 2 aberrations
per cell (taking into account all aberrations detected with mFISH), 0.5 and
1 simple exchanges per cell and 0.5 and 1 complex exchanges per cell for
the three energies of the C-ion beams used in the experiments. When the
dose-effect curves are not purely linear, the RBE value depends on the level
of damage, e.g. the RBE for the induction of 0.5 aberrations per cell by
extended Bragg peak C-ions is 3.17 ± 0.41 while it is 1.92 ± 0.19 for the
induction of two aberrations per cell. Table 3.1 shows, that only moderately
elevated RBE values are found for C-ions with an energy of 270 MeV/u, while
C-ions with an energy of 100 MeV/u and extended Bragg peak C-ions show
RBE values of about three. In addition, the RBEα values were determined
from the initial slopes of the dose-response curves. The RBEα values for the
induction of chromosomal aberrations were calculated from Figure 3.2.
3.1.4. C-ratio
The ratio of complex to simple exchanges, the so-called C-ratio is discussed
as a biomarker for densely ionizing radiation (see Section 1.3.6). The C-ratio
is derived from the dose-effect curves for the induction of simple and complex
exchanges. For the four investigated radiation types, Figure 3.4 shows that
the C-ratio increases for a given dose with increasing LET of the radiation,
confirming that a high C-ratio can indeed be regarded as a biomarker for
an exposure to densely ionizing radiation. However, comparison of different
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(a)
(b)
Figure 3.3.: Yield of chromosomal exchanges induced by different doses of
X-rays and C-ions with energies of 270 MeV/u and 100 MeV/u and extended
Bragg peak C-ions. (a) Simple exchanges, i.e. exchanges resulting from two
chromosome breaks. Data were fitted using linear functions. (b) Complex
exchanges, which are defined as aberrations involving three or more breaks in
at least two chromosomes. Lines were fitted using linear-quadratic functions
for X-rays and C-ions with energies of 270 MeV/u and 100 MeV/u or a linear
function for the extended Bragg peak C-ions. (Figures are taken from Hartel
et al. [2010].)
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C-ions C-ions C-ions
270 MeV/u 100 MeV/u ext. Bragg peak
0.5 aberrations/cell 1.54± 0.25 2.92± 0.38 3.17± 0.41
1 aberration/cell 1.34± 0.53 2.31± 0.24 2.51± 0.28
2 aberrations/cell 1.18± 0.17 1.79± 0.17 1.92± 0.19
0.5 simple exch./cell 1.22± 0.11 1.42± 0.13 1.51± 0.15
1 simple exch./cell 1.23± 0.10 1.42± 0.11 1.52± 0.14
0.5 complex exch./cell 1.08± 0.49 2.02± 1.32 2.47± 1.41
1 complex exch./cell 1.05± 0.38 1.66± 0.89 1.72± 0.74
initial slope 2.5± 0.6 5.5± 1.2 5.8± 1.2
Table 3.1.: RBE values for the induction of aberrations, simple and complex
exchanges in the in vitro irradiated peripheral blood lymphocytes of a healthy
donor. Aberrations were scored on mFISH stained metaphase spreads. RBE
values were calculated from the data shown in the Figures 3.2, 3.3 (a) and 3.3
(b). The RBEα values were determined from the initial slopes of the dose-
responsponse curves for the induction of aberrations (Figure 3.2). The errors
of the RBE values were calculated from the errors of the fit parameters of the
dose effect curves. exch. = exchanges.
Figure 3.4.: Ratio of complex to simple exchanges, C-ratio, as a function of
dose for the irradiation of lymphocytes with C-ions of different energies or
X-rays. The C-ratio is derived from Figure 3.3 (a) and (b).
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Figure 3.5.: Mean number of breaks per complex aberration induced by differ-
ent doses of X-rays or C-ions of different energies in isolated peripheral blood
lymphocytes irradiated in vitro.
doses of one radiation quality shows an increase of the C-ratio with the dose.
This makes it difficult to conclude whether an observed elevated C-ratio was
induced by densely ionizing radiation, or by a high dose of sparsely ionizing
radiation. For extended Bragg peak C-ion irradiation, the C-ratios for doses
of 1 Gy and 2 Gy are similar. However, to draw a definitive conclusion whether
the C-ratio for extended Bragg peak C-ions is dose-dependent or not, broader
dose ranges are necessary.
3.1.5. Complexity of complex exchanges
The mFISH method allows a detailed analysis of the complex aberrations
regarding the involved chromosomes and the number of breaks that were
necessary to produce the observed aberrations. Thus, not only the yield
of complex exchanges was investigated, which is shown in Figure 3.3 (b),
but also the complexity of each individual complex aberration. To show the
effect of the radiation quality and dose on the complexity of the induced
complex exchanges, the mean number of breaks per complex aberration was
calculated for each dose and radiation quality and is shown in Figure 3.5.
The mean number of breaks per complex aberration increases with the LET
in the investigated LET range, but as the C-ratio, the complexity of complex
aberrations is also dose-dependent and increases with higher doses.
3.1.6. Transmissible and non-transmissible exchanges
To investigate which fraction of induced aberrations can be passed to daugh-
ter cells without causing problems during cell division, the aberrations were
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divided into transmissible and non-transmissible ones and the ratio of trans-
missible to non-transmissible aberrations was calculated (see Table 3.2).
The ratio of (transmissible) translocations to (non-transmissible) dicentrics
with acentric fragments is close to one. Summing up translocations and di-
centrics for all radiation qualities and doses yields 735 translocations and 730
dicentrics indicating that translocations and dicentrics are induced with the
same probability.
Complex aberrations show a different pattern regarding their transmissi-
bility. The induction of non-transmissible complex aberrations is much more
frequent than the induction of transmissible ones. In addition, the fraction
of transmissible complex exchanges seems to decrease with increasing dose,
although large uncertainties at low doses hamper a statistical analysis.
3.1.7. Incomplete aberrations
The exchanges observed after in vitro exposure were analyzed regarding their
completeness as defined in a publication by Cornforth [2001] and described
in Section 2.6.4, i.e. the simple and complex exchanges were divided into the
groups of complete exchanges, incomplete exchanges and one-way exchanges.
Table 3.3 shows the numbers of observed exchanges and the fraction on in-
complete simple and incomplete complex exchanges. To achieve smaller error
bars, the fraction of incomplete exchanges was also calculated for both simple
and complex exchanges together. The fraction of incomplete exchanges in-
creases with dose. In addition, the fraction of incomplete exchanges increases
with increasing LET.
3.1.8. Distribution of aberrations and breaks in the cells
The distribution of aberrations in the the cells was analyzed. As shown in
Figure 3.6, the distributions of aberrations in the cells after irradiation with
different doses of X-rays are in good agreement with Poisson distributions
(Eq. 2.1), which are represented by the solid lines in the figure. The resulting
fit parameters a, the mean value of the Poisson distribution, are 0.83± 0.04,
1.57± 0.13, 2.20± 0.14 and 3.84± 0.22 for doses of 1, 2, 3 and 4 Gy. Thus the
mean value of induced aberrations per cell increases with dose. The maximum
number of aberrations in one cell increased from 3 aberrations per cell at a
dose of 1 Gy to 10 aberrations per cell at a dose of 4 Gy.
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Figure 3.6.: Distribution of aberrations in the cells induced by different doses
of X-rays. The solid lines represent a Poisson distribution fitted to the exper-
imental data.
To compare the effects of different radiation qualities, the distributions
of aberrations induced by 1 Gy and 2 Gy of X-rays and C-ions of different
energies are shown in Figure 3.7 (a) and (b). Poisson distributions were fitted
to the X-ray, 270 MeV/u and 100 MeV/u C-ion data, and are shown by the
solid lines in the figures. The resulting fit parameters a are given in Table 3.4.
For the extended Bragg peak C-ion data, it was found that a Neyman type
A distribution (Eq. 2.4) is in better agreement with the measured data than
a Poisson distribution. This can be expected, as described in Section 2.6.4,
by the inhomogeneous microscopic dose distribution of the densely ionizing
extended Bragg peak C-ions. The fit parameters λ, the mean number of
particle traversals per cell nucleus, and µ, the mean number of aberrations
induced by one particle traversal, are given in Table 3.5. The mean number
of aberrations per cell can then be calculated as the product of λ and µ and
is given in Table 3.5.
As mFISH allows a good analysis of the breaks that lead to the observed
aberrations, it is possible to determine the minimum number of breaks nec-
essary to produce the observed aberration(s) in each analyzed metaphase.
The resulting distribution of breaks involved in aberrations is given in Figure
3.8 for irradiation with different doses of X-rays and in Figure 3.9 (a) and
(b) for irradiation with X-rays, 270 MeV/u, 100 MeV/u and extended Bragg
peak C-ions with doses of 1 Gy and 2 Gy. As the analysis was performed in
metaphase cells 48 h after irradiation, the term “breaks per cell” refers to the
breaks that lead to the observed aberrations, not to the number of initially
induced breaks. The distributions show a up and down pattern with high
incidences of cells with 0, 2 and 4 breaks involved in aberrations and low fre-
quencies of cells with 1 and 3 breaks involved in aberrations. This is a result
of the different frequencies of the aberration types. Simple exchanges (i.e.
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(a)
(b)
Figure 3.7.: Distribution of aberrations in the cells induced by (a) 1 Gy and
(b) 2 Gy of X-rays, 270 MeV/u C-ions, 100 MeV/u C-ions and extended Bragg
peak C-ions. Solid lines were fitted using a Poisson distribution; dashed lines
represent a Neyman type A distribution fitted to the data.
Radiation quality 1 Gy 2 Gy
X-rays 0.38± 0.04 1.57± 0.13
C-ions 270 MeV/u 0.88± 0.10 1.84± 0.13
C-ions 100 MeV/u 1.11± 0.10 2.84± 0.17
Table 3.4.: Fit parameters a obtained from the Poisson distribution fitted to
the distribution of aberrations in the peripheral blood lymphocytes exposed
to doses of 1 and 2 Gy X-rays, 270 MeV/u C-ions and 100 MeV/u C-ions in
Figure 3.7.
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1 Gy 2 Gy
λ 2.6± 1.0 6.7± 3.4
µ 0.52± 0.22 0.41± 0.22
λµ 1.35± 0.77 2.7± 1.9
Table 3.5.: Fit parameters λ and µ obtained from the Neyman type A dis-
tribution fitted to the distribution of aberrations induced by extended Bragg
peak C-ions. The distribution of aberrations and the Neyman type A fit are
shown in Figure 3.7.
Figure 3.8.: Distribution of breaks involved in aberrations in the cells irradi-
ated with different doses of X-rays.
(a) (b)
Figure 3.9.: Distribution of breaks involved in aberrations in the cells induced
by (a) 1 Gy and (b) 2 Gy of X-rays, 270 MeV/u C-ions, 100 MeV/u C-ions and
extended Bragg peak C-ions.
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reciprocal translocations, dicentrics and centric rings) are the most frequent
chromosomal aberrations found after exposure to ionizing radiation, unless
very high doses or very high LET radiations are applied (see Table 3.2). Cells
carrying one simple exchange are therefore frequent and this explains the peak
at 2 breaks per cell. Two simple exchanges in one cell are the main contribu-
tion to the peak at 4 breaks per cell, only for high doses complex aberrations
with 4 breaks contribute to this peak to a large extend. Aberrations with one
break, i.e. excess acentric fragments, are less frequent (again, see Table 3.2).
This results in the low frequency of cells with one break. Three breaks in-
volved in aberrations in one cell are visible either as the result of one complex
aberration or as a simple exchange plus an excess acentric fragment. Excess
acentric fragments are rare, and complex aberrations are frequent after ex-
posure to high doses only leading to a reduced frequency of cells containing
three breaks involved in aberrations.
3.1.9. Time-dependence of aberration yield
High-LET radiation induces, in contrast to low-LET radiation, a pronounced
cell cycle delay of heavily damaged cells [George et al., 2001; Ritter et al.,
2002a,b; Gudowska-Nowak et al., 2005; Lee et al., 2005]. To see whether this
occurs in the LET range applied in this study, cells were harvested at 72 h
in addition to the standard harvesting time and analyzed using mFISH for
selected radiation qualities and doses. Table 3.6 compares the aberrations
observed in M1 cells after exposure to 2 Gy 270 MeV/u and extended Bragg
peak C-ions after 48 h and 72 h incubation. After exposure to 270 MeV/u C-
ions the fraction of aberrant cells, the mean number of aberrations per cell and
the incidences of simple and complex exchanges are in excellent agreement in
M1 cells incubated for 48 h and 72 h, indicating that there is no cell cycle delay
of heavily damaged cells. In contrast, in the cells exposed to extended Bragg
peak C-ions an increase in aberration frequency from 48 h to 72 h incubation
time is observed. This increase is highest for complex aberrations, where the
number of complex aberrations per cell increases by about 50%.
270 MeV/u C-ions Ext. Bragg peak C-ions
M48 h M72 h M48 h M72 h
aberrant cells (%) 87± 3.3 90± 2.9 89± 3 99± 1
aberrations/cell 1.79± 0.13 1.76± 0.13 2.75± 0.16 3.30± 0.18
simple exch./cell 1.15± 0.10 1.15± 0.11 1.37± 0.12 1.48± 0.12
complex exch./cell 0.27± 0.05 0.33± 0.06 0.84± 0.09 1.31± 0.11
Table 3.6.: Time-dependence of aberrations induced in peripheral blood lym-
phocytes by 2 Gy C-ions with an energy of 270 MeV/u and extended Bragg
peak C-ions. Aberration analysis was performed in M1 cells after 48 h and
72 h of incubation. exch. = exchanges.
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3.2. Aberrations in prostate-cancer patients
To monitor the cytogenetic effect of radiotherapy, blood samples from patients
with prostate cancer were obtained before, during and at the end of radiother-
apy as well as one year after treatment. Special interest was the comparison of
patients treated with a C-ion boost followed by IMRT with patients receiving
only IMRT. These two patient groups had similar tumor stages and target
volumes. A third group of patients was included in the study to investigate
the influence of the target volume on the aberration yield, to these patients a
larger PTV that included the pelvic lymph nodes was applied. Details about
the three patient groups have been given in Section 2.1.1.
3.2.1. In vitro irradiation of blood samples received before
therapy
A blood sample of about 8 ml was obtained from each patient before the
beginning of radiotherapy. The isolated lymphocytes were divided into two
samples, one served as unirradiated control to detect possible chromosomal
aberrations present before the beginning of therapy, the other was irradiated
in vitro with X-rays with a dose of 3 Gy to test for individual radiosensitiv-
ity (see Section 2.3.1). Blood samples of healthy volunteers were used for
comparison. Samples from all patients and healthy volunteers were analyzed
using FPG staining. The scoring of dicentrics was used as described in Section
2.6.1. Samples from selected patients and from one healthy volunteer were
additionally analyzed using mFISH.
The aberration yield observed in the unirradiated blood samples was low.
Analysis of FPG-stained slides yielded 9 dicentrics in 4250 analyzed cells
(=0.002 per cell) in the samples from patients and 0 dicentrics in 2300 an-
alyzed cells in the samples from healthy volunteers. Results of the mFISH
analysis are given in Table 3.7.
A sample of isolated peripheral blood lymphocytes from each patient was
exposed to 3 Gy X-rays. The yield of dicentrics (based on FPG analysis) is
given in Figure 3.10 for each individual patient and for the healthy volun-
teers. Each symbol in Figure 3.10 represents a different patient or healthy
volunteer. The mean values are very similar for the patient group and the
healthy volunteer group, 3 Gy of X-rays induced on average 1.00 ± 0.11 and
0.99± 0.05 dicentric chromosomes per cell in the patients and healthy volun-
teers, respectively. Remarkably, there is no outstanding radiosensitive patient
observed.
To investigate the variation of induced damage within a single individual,
two or more samples were obtained from some healthy volunteers at different
times. Samples from the same donor are displayed in Figure 3.10 by the same
symbol (e.g. upright triangle symbols and square symbols). From this it can
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Patients Health volunteer
scored cells 773 595
translocations 10 (1.29± 0.41) 1 (0.168± 0.168)
dicentrics 1 (0.129± 0.129) 1 (0.168± 0.168)
complex exchanges 1 (0.129± 0.129) 2 (0.336± 0.237)
all transmissible exchanges 10 (1.29± 0.41) 2 (0.336± 0.237)
all acentric fragmentsa) 10 (1.29± 0.41) 10 (1.68± 0.531)
Table 3.7.: Aberrations found in mFISH stained metaphase spreads from se-
lected patients (n=6) before therapy and in a sample from one healthy volun-
teer. Values in parentheses give the frequency of aberration per 100 cells. a)All
acentric fragments include fragments associated with dicentric chromosomes,
this modified scoring criterion is used to allow comparison with literature data
[Ramsey et al., 1995].
Figure 3.10.: Dicentrics observed in peripheral blood lymphocytes taken from
prostate-cancer patients before the beginning of therapy or from healthy vol-
unteers and exposed in vitro to 3 Gy X-rays. Patient symbols are the same
ones used in Figure 3.12, i.e. the three patient groups are represented by
solid (IMRT), patterned (C-ion boost plus IMRT) and open (IMRT*) sym-
bols. Identical symbols in the healthy volunteer data represent blood samples
obtained at different times from the same donor.
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Figure 3.11.: Chromosomal aberrations observed in peripheral blood lympho-
cytes from two patients and one healthy volunteer after in vitro exposure to
3 Gy X-rays using mFISH staining.
be seen that the variation within one donor is about as large as the variation
in the group of healthy donors.
The results of the mFISH stained samples are shown in Figure 3.11. The
frequencies of non-exchange aberration, simple and complex exchanges are
very similar in the analyzed patients’ and healthy volunteer’s samples, indi-
cating that there is no difference between patients and healthy individuals
regarding their response to ionizing radiation.
To compare the two staining methods FPG and mFISH, the yield of all
dicentric chromosomes observed with mFISH was determined (all dicentrics
were scored for this analysis, including dicentrics which are part of a com-
plex exchange). FPG analysis yielded 1.00 ± 0.11 and 0.99 ± 0.05 dicentric
chromosomes per cell in the patients and healthy volunteers groups after ex-
posure to 3 Gy X-rays, mFISH analysis yielded 0.85 ± 0.06 and 0.90 ± 0.09
dicentrics per cell in the healthy donors and patients, respectively, showing a
good agreement between the two staining methods regarding the recognition
of dicentric chromosomes.
3.2.2. Aberration yield during therapy course
To investigate the effect of the radiotherapy on the aberration yield blood
samples were obtained during therapy course. The results from aberration
analysis on mFISH stained slides are shown in Figure 3.12, where the yield
of chromosomal exchanges is plotted versus the dose applied to the target
volume. Each symbol in Figure 3.12 represents a different patient. Solid sym-
bols (green) represent patients treated with IMRT only (IMRT), patterned
symbols (blue) represent patients treated with C-ion boost followed by IMRT
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(C-ion boost + IMRT). Patients treated with IMRT with a larger target
volume including the pelvic lymph nodes (IMRT*) are represented by open
symbols (red). The yield of exchanges observed in the peripheral blood lym-
phocytes of prostate-cancer patients increases during the radiation therapy
course. The increase is most pronounced in the IMRT* patients.
Figure 3.12.: Exchange-type aberrations (i.e. simple and complex exchanges)
as a function of dose to the tumor (measured in Gy for IMRT treatment and in
GyE for the C-ion boost). Each symbol in the figure represents an individual
patient. (This figure is taken from Hartel et al. [2010].)
To study in more detail the differences between the three patient groups the
aberrations were classified into excess acentric fragments, simple exchanges
and complex exchanges and the data were pooled for each group. Figure 3.13
shows the aberrations for each patient group. Figure 3.13 reveals that pre-
dominantly simple exchanges are induced by the therapy in all three patient
groups. During therapy one sample was taken at the end of the C-ion boost
irradiation (which is after 6 daily fractions of 3 GyE) for the C-ion boost +
IMRT patient group and after irradiation with similar tumor doses for the
other two patient groups. A statistically significant increase is observed for
all three patient groups from the aberration yield measured before therapy to
the yield after the C-ion boost or similar doses of IMRT (p=0.023, p=0.012
and p=0.013 for the C-ion boost + IMRT, IMRT and IMRT* patient groups,
respectively, statistical significance was determined using t-test). At the end
of the therapy, the aberration yield was significantly higher in all three patient
groups than during the therapy (p=0.0002, p=0.0037 and p=0.0078 for the
C-ion boost + IMRT, IMRT and IMRT* patient groups, respectively).
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Figure 3.13.: Aberration spectrum observed in the three patient groups using
with mFISH technique. Note the different y-axis scale in the upper and lower
panel. Error bars represent standard errors of the mean.
During therapy, the two patients groups with the small PTV, C-ion boost
+ IMRT patients and IMRT patients, differ significantly with the aberration
yield being lower in the patients receiving C-ion boost (p=0.036). This is a
most important result regarding the future of C-ion therapy, as it proofs that
C-ion radiotherapy induces less aberrations in the peripheral blood lympho-
cytes, which represent the surrounding normal tissue than IMRT. The aber-
ration yield in the patient group with the large PTV (IMRT*) is significantly
higher than the aberration yield in the patients receiving C-ion boost + IMRT
and in the IMRT patients with the smaller PTV (p=0.030 and p=0.031).
At the end of the therapy, the difference between the two groups with the
small PTV, which was present during the therapy, is no longer observable
(p=0.38). The aberration yield in the IMRT* patients is significantly higher
compared to the C-ion boost + IMRT and IMRT patient groups (p=0.032
and p=0.036).
At the end of the C-ion boost, the ratio of complex to simple exchanges,
C-ratio, is higher in the C-ion boost + IMRT patients compared to the IMRT
patients (8/39 versus 7/61). However, this difference is statistically not sig-
nificant (p=0.22 using a one-sided Fisher’s exact test).
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3.2.3. Aberration yield one year after therapy
To study the persistence of aberrations in peripheral blood lymphocytes after
radiotherapy, a blood sample was obtained one year after therapy. The yield
of exchanges found by mFISH analysis in each patient is displayed in Figure
3.12.
The persistence of aberrations in the year after therapy was tested for each
patient individually using Fisher’s exact test on the number of aberrant cells.
Samples from 16 patients were available one year after therapy and from these
patients, only two showed a statistically significant decrease in the fraction
of aberrant cells in the first year after therapy (one patient from the IMRT*
group and one from the C-ion boost + IMRT group).
Figure 3.13 shows that the aberration pattern, i.e. the frequencies of excess
acentric fragments, simple and complex exchanges are also similar at the end
of therapy and one year after. Statistical analysis using t-test showed that
in the year after the therapy, no significant decrease was observed in any of
the three patient groups (p=0.17, p=0.48 and p=0.096 for the C-ion boost +
IMRT, IMRT and IMRT* patients, respectively).
3.2.4. Time-dependence of aberration yield
The aberration yield found in first metaphase cells exposed to densely ioniz-
ing radiation depends on harvesting time, as described in Section 3.1.9. To
investigate whether the C-ion boost induces a delay of heavily damaged cells,
cells were harvested at 72 h in addition to the standard harvesting time at
48 h and the yield of dicentric chromosomes was scored on FPG stained slides
in M1 cells. The resulting Figure 3.14 shows no time-dependent increase in
the aberration yield for any of the three patient groups.
3.2.5. Transmissibility of aberrations
The aberrations observed in the patients’ samples during and after therapy
were classified according to their transmissibility. The frequencies of trans-
missible and non-transmissible simple and complex exchanges observed in
the patients are given in Table 3.8. The resulting ratio of translocations to
dicentrics is close to one during and at the end of therapy, but one year af-
ter therapy more translocations than dicentrics are observed. Transmissible
complex aberrations are clearly less frequent than non-transmissible complex
aberrations. However, the low numbers of complex aberrations result in larger
uncertainties regarding the ratio of transmissible to non-transmissible com-
plex exchanges.
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Figure 3.14.: Yield of dicentric chromosomes found in peripheral blood lym-
phocytes of prostate-cancer patients at the end of the radiotherapy course
after 48 h and 72 h incubation. Dicentric scoring was performed in M1 cells
on FPG-stained slides. The symbols correspond to the individual patients.
3.2.6. Equivalent whole-body dose
The equivalent whole-body dose can be estimated by comparing the yield of
in vivo induced aberrations with the X-ray in vitro calibration curve which is
shown in Figure 3.2 [Durante et al., 1999]. At the end of therapy, the mean
values and standard errors of the induced exchanges for each patient group
corresponded to a total body dose of 0.39± 0.05 Gy for the C-ion boost plus
IMRT patients, 0.52± 0.10 Gy for the IMRT patients and 1.84± 0.25 Gy for
the IMRT* patients.
3.2.7. Rogue cell observed using mFISH staining
Rogue cells are multiaberrant cells including several dicentric and polycentric
chromosomes and numerous fragments. They are rarely observed in peripheral
blood lymphocytes (e.g. Mustonen et al. [1998]; Neel [1998]; Lazutka [1996]).
In one patient sample taken at the end of therapy, a metaphase was observed
displaying multiple aberrations involving 31 breaks in 25 chromosomes. Other
cells in this patient’s sample showed on average 0.15 aberrations per cell and
no other complex aberration was observed in 100 analyzed cells. Therefore
this cell was believed to be a rogue cell and was excluded from the analysis.
Figure 3.15 shows a DAPI and artificial color image of this cell together with
a karyotype. Most rogue cells reported in the literature were found on the
basis of solid staining, there is only one report about a rogue cell observed
in an mFISH stained lymphocyte metaphase. In this report an image of the
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multiaberrant cell is shown, but no attempt to analyze the exchanges was
made [Wahab et al., 2008].
(a) (b)
(c)
Figure 3.15.: Rogue cell (multiaberrant cell) found in a patient’s sample
stained with mFISH. (a) DAPI image. (b) Artificial color image. (c) The
analysis of the karyotype revealed that at least 31 breaks in 25 chromosomes
were necessary to produce the observed aberrations (four aberrations, two
reciprocal translocations (7’-14)(14’-7); (6’-16)(16’-6) and two complex ex-
changes with CAB (4/4/4) and (17/20/23)). All 46 centromeres were found.
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3.3. Analysis of damage produced in individual
chromosomes
3.3.1. Involvement of individual chromosomes in
aberrations
To address the question whether chromosomal aberrations occur in all chro-
mosomes with the same probability, the aberrations observed by mFISH were
analyzed regarding the distribution of breakpoints in the individual chromo-
somes.
Breaks in individual chromosomes in vitro
The breaks in the individual chromosomes 1 to 22 and in the X chromosomes
found after in vitro irradiation are shown in Table A.1. As the in vitro exper-
iments were performed with blood samples from one healthy female donor no
data for the Y-chromosome were obtained from these experiments. As men-
tioned earlier, the term “breaks” refers to breaks that lead to the observed
chromosomal aberrations, not to the initially induced breaks.
The number of breaks in the individual chromosomes was plotted versus
the chromosome number. The resulting Figure 3.16 shows a decrease of the
number of breaks involved in aberrations with increasing chromosome num-
ber. The chromosomes are sorted according to their length with chromosome
number one being the largest chromosome; the only exception is chromosome
X which has about the same length as chromosomes number 7 and 8.
In Figure 3.16, the distribution of breaks in the individual chromosomes is
compared to two models, the chromosome length model and the chromosome
surface model, which are described in Section 2.7.1. Both models differ con-
siderably from the observed results, a χ2 test yielded values of 101 and 74 for
the f - and f 2/3-model, respectively. χ20.01 = 40.3 for a significance level of 1%
and the number of degrees of freedom being 22.
Another possible correlation could be between the involvement in aberra-
tions and the gene density on the chromosome. Therefore, the breaks in the
individual chromosomes were plotted versus the gene density, which is given
in Table A.1. However, the resulting Figure 3.17 shows no correlation between
the gene density and the number of breaks involved in aberrations.
Breaks in individual chromosomes in vivo
The analysis of the distribution of breaks in individual chromosomes, which
is described in the previous section for in vitro irradiated samples, was also
performed for the samples obtained from the patients during and after the
therapy. The resulting distribution is given in Table A.2 and is shown in
Figure 3.18 together with the f - and f 2/3-models. A χ2 test yielded χ2 = 95
70 Chapter 3. Results
Figure 3.16.: Distribution of breaks in the individual chromosomes. Data
were obtained from the analysis of mFISH stained metaphases after in vitro
irradiation (results from all in vitro experiments were pooled).
Figure 3.17.: Distribution of breaks in the individual chromosomes. Breaks
are plotted versus gene density (genes per mega-basepair (Mbp) length). Data
were obtained from the analysis of mFISH stained metaphases after in vitro
irradiation.
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Figure 3.18.: Distribution of breaks in the individual chromosomes. Data
were obtained from the analysis of mFISH stained metaphases after in vivo
irradiation (i.e. lymphocytes obtained from prostate-cancer patients during,
at the end and one year after radiotherapy).
and χ2 = 41 for the f - and f 2/3-model, respectively. χ20.01 = 41.6 for a
significance level of 1% and the number of degrees of freedom being 23 (one
more as for the in vitro data, as in the in vivo data one X and Y chromosome
was present, in contrast to the in vitro data where two X chromosomes were
present).
3.3.2. Exchange frequencies between chromosome pairs:
statistics for chromosome interphase positioning
SCHIP
The exchange frequencies between pairs of chromosomes were analyzed by
using the SCHIP software, which is described in Section 2.7.2. As it was
found during this work that the number of entries in the table must be as
high as possible for a successful search for chromosome clusters, data from
all experiments were pooled for the analysis. A table with 5223 entries was
achieved and was uploaded to the SCHIP homepage to search for clusters.
The resulting Table A.3 shows the number of cells with exchanges between
chromosomes i and j, the calculated normalized single chromosome partici-
pation factors g(i) and the deviations from the expected values assuming a
random model ∆(i, j).
The candidate clusters for lymphocytes provided at the SCHIP homepage
(taken from literature) were tested for significance in the data set. These
candidate clusters are (1;16;17;19;22) [Boyle et al., 2001], (6;7) [Pombo et al.,
1998], (8;11) [Nagele et al., 1999], the Philadelphia Chromosome found in
most chronic myeloid leukemia (9;22) [Mitelman et al., 2007], (13;21) [Alcobia
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et al., 2000], (13;14;15;21;22) [Krystosek, 1998], (14;18) [Lukasova et al., 1999],
(14;22) [Alcobia et al., 2000]; (15;17) [Neves et al., 1999] and (17;19;20) [Cre-
mer et al., 2003]. The resulting p-values for the provided candidate clusters
are shown in the upper part of Table 3.9. From the 10 provided clusters only 4
are significantly different from the random model and yielded p-values below
0.05. One of them was the cluster of acrocentric chromosomes (p ≤ 0.0001,
highly significant deviation from the random model), which are known to be
located in close proximity to each other around the nucleoli, as described in
Section 2.7.2. Thus, the SCHIP method applied to the present data set was
able to confirm the clustering of the acrocentric chromosomes.
Next, own candidate clusters were searched on the basis of the ∆(i, j) values
and tested for significance in the data set. Altogether, 30 cluster candidates
were tested and all yielded p-values below 0.05, as can be seen from the lower
part of Table 3.9. However, the choice of candidate clusters on the basis of
the ∆(i, j) values of the data set in which they are tested later is biased, as
false-positives (which are to be expected from the table size and the choice
of p=0.05 as significance level) could be depicted. The candidate clusters
chosen on the basis of the data reported here were therefore tested in the
largest table provided at the homepage of SCHIP, i.e. a table published by
Arsuaga et al. [2004] (3700 table entries). The numbers of lymphocytes with
exchanges between all chromosome pairs, the single chromosome participation
factors g(i) and the ∆(i, j) values for this data set are given in Table A.4.
The resulting p-values are shown in the right column of Table 3.9. From
the 10 provided candidate clusters 2 reached p-values below 0.05, from the
30 candidate clusters chosen on the basis of the present data set, 24 yielded
p-values below 0.05 in the data set published by Arsuaga et al. [2004]. This
indicates that at least some of the candidate clusters chosen in the present
data set are indeed chromosome clusters and not false-positive results.
The own candidate clusters were also tested for significance in other lym-
phocyte data sets provided at the SCHIP homepage. For the 30 candidate
clusters tested, p-values below 0.05 were found for 10 candidate clusters in
the data set provided by Cornforth et al. [2002] (1877 table entries), for 13
candidate clusters in the table provided by Loucas and Cornforth [2001] (786
table entries) and for 11 candidate clusters in the data set provided by Corn-
forth and Loucas (unpublished data, iron ion irradiation, 959 table entries)
(these data are not shown). This indicates that large tables are essential for
a successful search for candidate clusters.
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Candidate cluster present study published data(a)
(1;16;17;19;22) 0.0281 0.0006
(13;14;15;21;22) 0.0000 0.0013
(17;19;20) 0.3915 0.4692
(13;21) 0.0001 0.5105
(14;22) 0.4524 0.2055
(6;7) 0.9315 0.8383
(9;22) 0.0744 0.6622
(15;17) 0.8001 0.5783
(14;18) 0.0002 0.4767
(8;11) 0.4057 0.085
(5;7;11;12;19) 0.0000 0.0003
(4;8;13;14;18) 0.0000 0.0000
(4;8;13;14) 0.0000 0.0004
(9;16;20) 0.0000 0.1333
(4;10;13;14) 0.0001 0.016
(8;13;14;18) 0.0000 0.0000
(3;6;10) 0.0003 0.0108
(3;6;10;12) 0.0003 0.0007
(2;12;17) 0.0003 0.0455
(9;16;18;20) 0.0000 0.0008
(16;20;22) 0.0000 0.001
(15;16;20;22) 0.0000 0.0005
(7;12;17;19) 0.0000 0.0196
(5;7;12;19) 0.0000 0.0142
(1;15;22) 0.0000 0.0033
(9;16;20;22) 0.0000 0.0274
(2;12;17;19) 0.0001 0.1015
(1;9;16) 0.0079 0.0652
(1;3;6;10) 0.0000 0.0511
(9;15;16;20) 0.0000 0.0150
(4;8;13;18) 0.0000 0.0013
(3;6;12;17) 0.0000 0.0285
(2;3;17) 0.0032 0.0408
(2;3;6;17) 0.0005 0.0385
(15;20;22) 0.0000 0.1704
(1;9;22) 0.0011 0.0140
(1;16;22) 0.0105 0.0004
(16;19;20;22) 0.0000 0.0000
(9;16;22) 0.0006 0.1842
(1;9;16;22) 0.0000 0.0032
Table 3.9.: P-values for candidate clusters tested in the table of pairwise chro-
mosomal exchanges of the present work and in a published data set ((a) Ar-
suaga et al. [2004]). Upper part: candidate clusters suggested in the literature
as provided at the SCHIP homepage. Lower part: own candidate clusters cho-
sen on the basis of the ∆(i, j) values of Table A.3.

4. Discussion
4.1. Cytogenetic effects of sparsely and densely
ionizing radiation - in vitro experiments
Knowledge of the cytogenetic effects of sparsely and densely ionizing radia-
tion is of great importance. In cancer therapy, X-rays and particle beams
are used to irradiate tumors. While X-rays are widely used in radiotherapy
for many years, the application of charged particle beams is comparably new
and applied only at a few facilities [Skarsgard, 1998; Schulz-Ertner, 2009].
Especially when young patients are treated there is concern about the risk of
secondary malignancies or non-malignant diseases that arise from the damage
induced in the normal tissue surrounding the tumor [Hall and Wuu, 2003;
Dickerman, 2007]. Better knowledge about the cytogenetic effects of the dif-
ferent radiation qualities can help to predict the late effects of radiotherapy.
As transmissible aberrations are the crucial aberration type regarding the risk
of secondary cancers, the mFISH technique, which reveals all types of inter-
chromosomal rearrangements including transmissible ones, was applied in the
work presented here.
Another field where the knowledge about the cytogenetic effects of differ-
ent radiation qualities is of interest is space travel. In manned space missions,
the health risk associated with the exposure to galactic cosmic radiation is
aﬄicted with large uncertainties, as little is known about the biological ef-
fects of these radiation qualities [Durante and Cucinotta, 2008]. A third field
where cytogenetic effects of radiation exposure are investigated is biological
dosimetry. In case an individual was exposed to ionizing radiation, retrospec-
tive dose estimation using biological dosimetry together with physical dose
estimation is important for choosing an adequate treatment [International
Atomic Energy Agency, 2001].
The main purpose of the study presented here was to gain information
about the cytogenetic effects of the radiation qualities applied in radiother-
apy and to compare the cytogenetic effects in vitro with those of different
radiotherapy regimes in vivo. The radiation qualities used for this work were
chosen accordingly, i.e. the C-ion energies cover the energy range which is
typical for tumor therapy.
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4.1.1. Analysis of dose-response curves for the induction of
aberrations
One of the main purposes of the present work was to generate dose-effect
curves that can be used for comparison with the in vivo results of prostate-
cancer patients that underwent radiotherapy. As these patients were treated
either with photon IMRT or a combination of IMRT and C-ion boost, the in
vitro experiments focused on these radiation qualities as well. The mFISH
method was used which allows full analysis of chromosomal interchanges.
Photon dose-effect curve
For photon irradiation, a detailed study by Loucas and Cornforth [2001] de-
scribes the dose dependence of aberrations induced by γ-rays in human pe-
ripheral blood lymphocytes using mFISH technique. Doses of 0, 1, 2, and 4 Gy
were applied and cells were cultured for 48 h. mFISH analysis was performed,
and aberrations were classified according to their complexity (terminal dele-
tions, simple exchanges, complex exchanges), their completeness and trans-
missibility. The simple and complex exchanges observed in the present study
and in the study by Loucas and Cornforth [2001] are compared in Figure 4.1.
Figure 4.1.: Comparison of the number of simple and complex exchanges in-
duced by X-ray and γ-ray exposure. X-ray data taken from Figure 3.3, γ-ray
data taken from Table 2 in a publication by Loucas and Cornforth [2001]. In
both studies, mFISH analysis was performed on peripheral blood lymphocytes
after 48 h in vitro growth.
The mean number of exchanges per cell was higher in the study presented
here compared to the data obtained by Loucas and Cornforth [2001]. However,
taking into account that the results were obtained in different laboratories and
that the used photon energies were different, the dose-effect curves in Figure
4.1 show a very good similarity between both data sets. From Figure 4.1,
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an attempt was made to estimate the RBE of X-rays compared to γ-rays. A
higher RBE for chromosomal aberrations induced in peripheral blood lym-
phocytes for X-rays compared to γ-rays was found by the scoring of dicentric
chromosomes and acentric fragments on solid stained sides (reviewed by Hill
[2004]). From Figure 4.1, which is based on mFISH analysis, the RBEα (i.e.
the comparison of the initial slopes of the fitted curves), which is used in the
review by Hill [2004], was calculated to be 1.8 for the induction of simple
exchanges, which is in good agreement with the RBEα values of 1.5 and 2.8
reported in the review by Hill [2004]. The RBEα for the induction of com-
plex exchanges was not calculated as the initial slope of the fit-curve for the
complex exchanges is around zero in both data sets as can be seen in Figure
4.1. The RBE of 250 kV X-rays compared to γ-rays was calculated to be 1.4
for the induction of 0.5 simple exchanges per cell, 1.2 for the induction of 1
simple exchange per cell and 1.3 for the induction of 0.5 complex aberrations
per cell.
Dose-effect curves for charged particles
Determining the RBE of C-ions with different energy for the induction of
different aberration types was one of the main purposes of this work. To
calculate the RBE it was necessary to measure dose-effect curves. Other
studies that addressed the cytogenetic effects of heavy ions by means of the
mFISH method used only one or two doses, and therefore no dose-effect curves
were achieved in these studies [Durante et al., 2002; Anderson et al., 2003;
Wu et al., 2003; Pignalosa et al., 2008].
However, studies applying other staining techniques exist, that obtained
dose-effect curves for the induction of aberrations by heavy ion irradiation.
For example, Nasonova and Ritter [2004] reported about the exposure of
human peripheral blood lymphocytes to X-rays and extended Bragg peak
C-ions (LET 60–85 keV/µm). Analysis of metaphase cells and prematurely
condensed chromosomes (PCC) in G2 cells was performed on FPG stained
slides. Extended Bragg peak C-ions were more effective in inducing aber-
rations in metaphase cells, and the dose-effect curves for X-rays showed a
linear-quadratic behavior while extended Bragg peak C-ion irradiation re-
sulted in a linear dose-response curve, in agreement with the results obtained
in the present study.
4.1.2. Relative biological effectiveness for cytogenetic
damage
Since the first publication on RBE for the induction of cytogenetic damage
in 1967 by Skarsgard [Skarsgard et al., 1967] the effectiveness of different ra-
diation qualities in inducing chromosomal damage was investigated in many
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studies (a recent review can be found in Ando and Kase [2009]). For lym-
phocytes, George et al. [2003a] reported a RBEα value of 2.4 ± 0.2 for the
induction of total exchanges by C-ions with an energy of 290 MeV/u; ex-
changes were detected using two-color FISH. In the present study, a RBEα
value of 2.5± 0.6 was derived from Figure 3.2 for the induction of aberrations
by 270 MeV/u C-ions, which is in good agreement with the data reported by
George et al. [2003a]. In a report by Monobe and Ando [2002], the initial
slopes of the dose-effect curves for the induction of dicentric chromosomes in
peripheral blood lymphocytes by 290 MeV/u C-ions passively decelerated to
an average LET of 50 keV/µm and X-rays are reported. From this, a RBEα of
3.3± 0.4 was calculated. This is lower than the RBEα values obtained in the
present study for the induction of aberrations in lymphocytes by C-ions with
an energy of 100 MeV/u and extended Bragg peak C-ions, RBEα=5.5 ± 1.2
and RBEα=5.8± 1.2 respectively, derived from Figure 3.2. However, the use
of passive energy reduction, in contrast to the active energy variation used in
the study reported here, may be the reason for the lower RBE observed in
the study by Monobe and Ando [2002], as passive energy degradation leads
to range straggling and the production of light fragments including neutrons.
In the present study, mFISH analysis was used to generate the dose-effect
curves of X-rays and C-ions with three different energies. This is the first
set of dose-effect curves for chromosomal aberrations induced by heavy ions
measured with mFISH. The mFISH analysis allowed calculating not only the
RBE values for the total aberrations, but for different aberration categories
like simple exchanges and complex exchanges separately. It was found that
the RBE for complex exchanges is higher than for simple exchanges after
irradiation with 100 MeV/u and extended Bragg peak C-ions (see Table 3.1).
In the tumor therapy with C-ions, this high biological effectiveness ensures
the inactivation of the tumor cells. Especially the high RBE for complex
exchanges is important, as they are mostly non-transmissible leading to the
death of the damaged cell (see Tables 3.2 and 3.8). On the other hand, the
high RBE radiation must be restricted to the tumor tissue as precisely as
possible to avoid severe side effects in the surrounding tissue. Therefore the
raster scanning technique and the active energy variation are advantageous,
as they ensure a good tumor conformation.
4.1.3. Complex aberrations - a biomarker for densely
ionizing radiation
A biomarker for the exposure of cells to densely ionizing radiation has been
suggested in several studies (e.g. Anderson et al. [2000]; Deng et al. [2000];
Brenner et al. [2001]; Anderson et al. [2003]). The most promising biomarker
candidate is the C-ratio, the ratio of complex to simple exchanges. An el-
evated C-ratio is found after in vitro exposure to densely ionizing radiation
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compared to photons in several studies applying different staining methods
(e.g. Testard et al. [1997]; Wu et al. [2003]; George et al. [2003b]; Johannes
et al. [2004]). This is confirmed by the present study, where an increasing
C-ratio was observed with increasing LET (see Figure 3.4). However, Figure
3.4 also shows that the C-ratio is dose-dependent in the LET range investi-
gated in this work, e.g a C-ratio of 0.5 is induced by about 4 Gy X-rays and
2 Gy 100 MeV/u C-ions. The highest C-ratio observed here is 0.92±0.10 after
4 Gy 100 MeV/u C-ions; however, a similar C-ratio is found after a dose of
6 Gy X-rays [Lee et al., 2010]. Therefore it is necessary to compare not only
the C-ratio, but also the aberration yield observed in a sample exposed to a
unknown radiation quality with the known dose-effect curves, to determine
whether an observed high C-ratio was induced by high-LET particles or by
high doses of low-LET radiation. Consequently, application of the C-ratio
in biological dosimetry to determine the radiation quality to which the vic-
tim was exposed will be very sophisticated, as the victim was probably not
exposed to a monoenergetic homogeneous beam, but to a mixture of energies.
4.1.4. Completeness of exchanges - is there an influence of
dose and LET?
Although it was not a main topic of this work to analyze the chromosomal
aberrations regarding their completeness, it was carried out as this informa-
tion is easily obtained in parallel to the normal mFISH analysis. Table 3.3
shows the chromosomal exchanges observed after in vitro irradiation classified
according to their completeness, i.e. distinguishing complete, incomplete and
one-way exchanges, following the definitions made by Loucas and Cornforth
[2001]. As can be seen from Table 3.3, a dose-dependent increase in the frac-
tion of incomplete simple exchanges was found in the experiments reported
here. This is in contrast to the findings by Loucas and Cornforth [2001]
where in lymphocytes irradiated with γ-rays a dose-independent fraction of
incomplete simple exchanges (of 2.3–2.4%) was found. Regarding the complex
aberrations, lower numbers hamper a definite conclusion wheter the fraction
of incomplete complex exchanges increases with dose as well. To yield smaller
error bars (higher number of exchanges) the simple and complex exchanges
were summed and analyzed regarding the fraction of incomplete exchanges
(right column in Table 3.3). An increase in the fraction of incomplete ex-
changes with increasing dose is observed then. In addition, an increase with
LET is observed as well, e.g. for a dose of 1 Gy the fraction of incomplete
exchanges increases from 0.014±0.014 to 0.088±0.029 and for a dose of 2 Gy
from 0.039± 0.018 to 0.110± 0.023.
Regarding the one-way exchanges, Loucas and Cornforth [2001] found that
the fraction of simple one-way exchanges is independent of dose, while the
fraction of complex one-way exchanges increases with dose. In the present
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study, the fraction of simple one-way exchanges varied from 10% to 25%
with no dose-dependence or LET-dependence visible (calculated from the data
displayed in Table 3.3), which is in good agreement with the fraction of 14% to
29% found by Loucas and Cornforth [2001]. For the fraction of complex one-
way exchanges, values between 15% and 80% were found in the present work,
but in contrast to the findings by Loucas and Cornforth [2001] no general
dose-dependence was observed (an increase with dose is found for the X-ray
and spread-out Bragg peak C-ion data, while a decrease with increasing dose
is observed after 270 MeV/u C-ion exposure and no correlation is found for
100 MeV/u C-ions).
Other studies with high statistical power are necessary to confirm or dis-
prove the findings about the dose- and LET-dependence of the fractions of
incomplete and one-way simple and complex exchanges. However, as the
dose-dependent increase in the fraction of incomplete exchanges was found
in all four data sets of the present study, and the LET-dependent increase
was found for both doses which were applied in all four data sets, a dose-
and LET-dependent increase of the fraction of incomplete exchanges can be
assumed from the present study.
4.1.5. Fate of aberrant cells
To understand the mechanisms involved in aberration formation it is most
useful to investigate aberrations in cells soon after irradiation, i.e. in G2-PCC
cells or in first cycle metaphase (M1) cells. The latter were used in the present
study. However, for the late effects of tumor therapy the long-term survival
of cells carrying an aberration is more relevant than the initial damage. The
aberrations induced in the peripheral blood lymphocytes by in vitro irradia-
tion with different radiation qualities were therefore analyzed regarding their
transmissibility. With regard to simple exchanges, it can be seen from Table
3.2 that translocations (which are transmissible) and dicentric chromosomes
with acentric fragments (which are non-transmissible) are induced with the
same frequency, therefore about half of all simple exchanges are transmissi-
ble. (Centric ring chromosomes with acentric fragments are non-transmissible
simple intrachanges, but they are rare compared to dicentrics and transloca-
tions, not affecting the ratio of transmissible to non-transmissible exchanges
substantially.) This is in line with several studies and theoretical predictions
(see e.g. Lucas et al. [1996]; Loucas and Cornforth [2001]). Therefore half
of the cells carrying a simple exchange are assumed to die during the next
few replication rounds. In a study by Pignalosa et al. [2008], the numbers of
dicentrics and translocations found in lymphocytes incubated 144 h after ir-
radiation with X-rays and iron ions were analyzed using arm-specific mFISH.
Translocations were about twice as frequent as dicentrics, indicating that di-
centrics indeed die out during a few replication rounds. In an experiment
by Durante et al. [2006], RxFISH was used on lymphocytes incubated for
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144 h after irradiation with gamma rays and iron ions and a higher yield of
translocations compared to dicentrics was found as well.
In contrast to simple exchanges, most complex aberrations induced by ion-
izing radiation are non-transmissible (see Table 3.2). Thus, albeit complex
aberrations seem to be the more severe damage to a cell compared to simple
exchanges, the majority of cells carrying a complex exchange will die and will
therefore not increase the risk of secondary malignancies induced by radio-
therapy.
As can be seen from Figure 3.4, the fraction of complex aberrations induced
in cells is high after exposure to high-LET radiation or exposure to high doses
of low-LET radiation. Regarding the risk of late effects of radiotherapy this
strongly underlines the advantage of C-ion radiotherapy, where a comparably
small volume of normal tissue is exposed to radiation, and this radiation
induces a higher fraction of complex exchanges compared to X-rays causing
the damaged cells to die rather than to continue growing. Compared with
C-ion radiotherapy, IMRT exposes a large volume of normal tissue to low or
moderate doses. Such an exposure of large volumes to lower doses can increase
the risk of secondary cancers [Hall and Wuu, 2003; Hall, 2006].
4.1.6. Distribution of aberrations in the cells
While the distribution of aberrations induced in first cycle metaphase cells by
X-rays or other sparsely ionizing radiation follows a Poisson distribution, the
experimental results after exposure to densely ionizing heavy ions are better
described by a Neyman type A distribution [Virsik and Harder, 1981; Lee,
2006; Gudowska-Nowak et al., 2007] (see Figure 3.7). The Neyman type A
distribution takes into account the microscopically inhomogeneous dose dis-
tribution of densely ionizing radiation. In the present study, it was found
that the distributions of aberrations induced by X-rays, 270 MeV/u C-ions
and 100 MeV/u C-ions are in good agreement with Poisson statistics, while
the distribution found after extended Bragg peak C-ion exposure is better de-
scribed by a Neyman type A distribution. Regarding the tumor therapy with
heavy ions, this result is most favorable, as it confirms that only in the case of
extended Bragg peak C-ions the inhomogeneous local dose distribution typi-
cal for densely ionizing particles is relevant for the cytogenetic effects, while
270 MeV/u C-ions and 100 MeV/u C-ions, which are found in the entrance
channel of the beam, i.e. in normal tissue, show a more X-ray-like behavior.
The parameter λ of the Neyman type A distribution corresponds to the
mean number of particle traversals per cell nucleus. It was found to be 2.6±1.0
and 6.7± 3.4 for irradiation with 1 Gy and 2 Gy extended Bragg peak C-ions
(see Table 3.5). The particle traversals per cell nucleus calculated from the
particle fluence and a mean cell nucleus are of 25µm2 were 2.15 and 4.3
for 1 Gy and 2 Gy extended Bragg peak C-ions (see Table 2.5). Thus, the
fit parameters of the Neyman type A distribution are in agreement with the
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values calculated from the particle fluence. The parameter µ of the Neyman
type A distribution describes the mean number of aberrations induced by one
particle traversal. It was found to be 0.52 ± 0.22 and 0.41 ± 0.22 for 1 Gy
and 2 Gy extended Bragg peak C-ions. Thus, as can be expected, the average
number of aberrations induced by a single particle traversal does not depend
on the applied dose.
4.1.7. Time-dependence of aberrations
The standard protocol for the preparation of M1 cells from human peripheral
blood lymphocytes schedules one sampling time at 48 h after the onset of the
culture. However, high-LET radiation produces a pronounced cell cycle delay
[Scholz et al., 1994; George et al., 2001; Ritter et al., 2002b; Tenhumberg
et al., 2007]. Thus, if only one sampling time is used this would result in an
underestimation of the damage induced by high-LET radiations because of
the delay of heavily damaged cells [Scholz et al., 1998]. In the present study,
a second sampling time 72 h after onset of the culture was therefore used in
addition to the standard sampling time at 48 h. No increase in aberration
level with sampling time in M1 cells was found after cell exposure to 2 Gy
270 MeV/u C-ions. A moderate cell cycle delay of heavily damaged cells was
found after exposure to 2 Gy extended Bragg peak C-ions, the aberration yield
found in M1 cells collected at 72 h was 20% higher than in cells collected at
48 h (see Table 3.6). In contrast, for 9.5 MeV/u C-ions (LET=175 keV/µm) a
pronounced delay of heavily damaged cells is reported by Lee et al. [2010] (in
this publication, for 2 Gy of 9.5 MeV/u C-ions a 5-fold increase in aberration
yield from 48 h to 72 h sampling time is reported for lymphocytes analyzed
using mFISH). The findings are in line with previous publications [Anderson
et al., 2000; George et al., 2001; Ritter et al., 2002a; Nasonova and Ritter,
2004] where no effect of the sampling time on the aberration yield for LET
values below 30 keV/µm was found.
4.2. Background aberration level and test of
individual radiosensitivity
In the present study, the aberration yield in peripheral blood lymphocytes
from prostate-cancer patients during the course of radiotherapy with IMRT
and C-ion boost was investigated to search for differences between the radio-
therapy schemes. To ensure that the aberration level in the patients before the
beginning of the therapy was similar to the one found in control populations,
a blood sample from every patient was taken before the onset of radiotherapy
and the cytogenetic damage in the lymphocytes was analyzed. In addition,
a part from this sample was irradiated in vitro to search for extraordinarily
radiosensitive patients.
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4.2.1. Background aberration level
The cytogenetic damage in peripheral blood lymphocytes is a sensitive tool for
detecting the exposure of individuals to mutagens and carcinogens, including
radiation. To detect small increases in the aberration level, a precise knowl-
edge about the aberration level in unexposed control groups is essential. Many
studies have therefore focused on the measurement of aberration frequencies
in control populations, using classical cytogenetic methods or fluorescence in
situ hybridization (FISH). Studies investigating translocation frequencies are
of special interest as translocations are believed to be transmissible through
the cell cycle, and an exposure to a mutagen or carcinogen can be detected
by an increased yield of translocations even decades after the exposure. The
use of the dicentric chromosome frequency as a monitor of exposure is lim-
ited to the detection of recent or ongoing events since cells with dicentrics
are unstable and will not be maintained in the peripheral blood lymphocytes
[International Atomic Energy Agency, 2001].
An early study using FISH for the investigation of aberration levels in con-
trol populations is reported by Ramsey et al. [1995], this study also addressed
the question of possible influence of age and lifestyle factors. Peripheral blood
lymphocytes from 91 subjects ranging from newborn to adults up to 79 years
old were investigated. The analysis revealed a clear age-dependent increase of
transmissible aberrations, increasing 10-fold from the cord blood of newborn
to the adults older than 50 years. The increase in dicentrics and acentric
fragments was less pronounced. In the study reported here 1.3 stable aber-
rations per 100 cells were found in the mFISH analyzed patients’ samples
taken before therapy, and 0.3 stable aberrations in the unirradiated samples
from one healthy volunteer (see Table 3.7). Both values are lower than in the
study reported by Ramsey et al. [1995] where in adults 50 years and older 2.5
stable aberrations per 100 cells were found. Ramsey et al. [1995] found 0.126
dicentrics per 100 cells and 0.24 acentric fragments per 100 cells, while in the
present study 0.13 dicentrics per 100 cells and 1.3 acentric fragments per 100
cells were found in patients’ samples and 0.17 dicentrics per 100 cells and 0.67
acentric fragments per 100 cells in the samples from a healthy volunteer ana-
lyzed with mFISH. The FPG analysis revealed on average 0.2 dicentrics per
100 cells in the patients’ samples. Thus, while the dicentric yields are in good
agreement, more acentric fragments were observed in the present study com-
pared to Ramsey et al. [1995]. In addition to the age-dependence discussed
here, the study by Ramsey et al. [1995] found other factors significantly asso-
ciated with the frequency of stable aberrations, these are smoking, consump-
tion of diet drinks/diet sweeteners, exposure to asbestos or coal products and
having a previous major illness.
Other studies addressed the background level and age-dependence of aber-
rations as well [Sorokine-Durm et al., 2000; Tawn and Whitehouse, 2001;
Vorobtsova et al., 2001; Whitehouse et al., 2005]. The aberration levels re-
84 Chapter 4. Discussion
ported there are generally in agreement with the aberration levels found in
the patients’ samples before the beginning of therapy and the sample of a
healthy volunteer reported here.
A study reported by M’kacher et al. [2003] addressed the question whether
there is a difference in the background aberration level in lymphocytes from
cancer patients and healthy volunteers. For this, they investigated the chro-
mosomal aberrations in Hodgkin’s lymphoma patients and two groups of con-
trol individuals, healthy donors and cancer patients (thyroid, urologic, head
and neck) before treatment. This study did not find a significant difference
in the level of aberrations between the cancer patients group and the healthy
volunteers group, which is in agreement with the results reported here (see
Section 3.2.1).
4.2.2. In vitro test to determine individual radiosensitivity
In the present work, blood samples obtained from the patients before therapy
were irradiated in vitro with 3 Gy X-rays to examine the individual radiosen-
sitivity. The main goal was to find possible outliers. Some genetic defects are
correlated with an extremely high radiosensitivity (e.g. patients with ataxia-
telangiectasia [Gatti, 2001], Nijmegen breakage syndrome or Fanconi anemia
[Obe and Vijayalaxmi, 2007]). Irradiating a patient with such a gene defect
would result in severe side effects for the patient and would lead to unexpected
results in the in parallel performed study investigating the cytogenetic damage
induced by radiotherapy in peripheral blood lymphocytes. Such outliers were
not observed in the patient group investigated in this study, as can be seen
in Figure 3.10. It is also visible from Figure 3.10 that the aberration frequen-
cies induced in the patients and in healthy volunteers are similar, indicating
that the patients have no elevated radiosensitivity. Furthermore, Figure 3.10
shows a considerable variation within samples taken from the same healthy
donor at different times.
In addition to the identification of outliers with an extremely high radiosen-
sitivity, in vitro tests may predict the risk of acute reactions after radiother-
apy. A publication by Borgmann et al. [2008] proposes the in vitro exposure
of peripheral blood lymphocytes to a dose of 6 Gy X-rays and the scoring of
excess acentric fragments. In this report the mean value (MV) and standard
deviation (SD) of the excess fragments per cell were determined. The pa-
tients with less excess fragments per cell than MV–SD were categorized as
radioresistant, patients that had between MV–SD and MV+SD excess frag-
ments per cell were categorized as normal and patients with an higher yield
than MV+SD were categorized as radiosensitive. With this categorization,
a correlation between in vitro radiosensitivity and fraction of patients with
severe side effects was observed. The knowledge of the radiosensitivity of each
individual patient is of course highly useful, as treatment schemes could be
adapted to reduce severe side effects in the group of sensitive patients by re-
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ducing the total dose and to enhance the tumor control rate by giving higher
doses to radioresistant patients. Although this seems highly desirable, such
an attempt was outside the aims of the study reported here. However, the
inter-individual variation found in the present study can be compared to the
variation reported by Borgmann et al. [2008], although the absolute values
are not comparable because different scoring criteria were used and different
X-ray doses were applied. In the present study, 1.00 ± 0.11 (MV ± SD) di-
centrics per cell were observed after 3 Gy of X-rays, in the study reported by
Borgmann et al. [2008], 3.29±0.55 and 3.59±0.57 (MV ±SD) excess acentric
fragments per cell were observed. Thus, the variation found in the present
study is smaller than in the study published by Borgmann et al. [2008].
4.3. Chromosomal aberrations induced by
radiotherapy
Radiotherapy for tumor treatment, alone or in combination with surgery or
chemotherapy, improves steadily resulting in an increasing probability of can-
cer cure and patient survival. A long-term survival of patients brings atten-
tion to the risk of radiation-induced secondary cancer and of late tissue injury
[Allan and Travis, 2005; Suit et al., 2007]. Radiotherapy must therefore be
optimized to minimize the risk of secondary diseases, while providing good
tumor control. Chromosomal aberrations in peripheral blood lymphocytes
are a useful tool to monitor the cytogenetic damage induced by radiation and
to estimate the risk of late effects.
4.3.1. Influence of radiation quality and target volume on
aberration yield
In this study, chromosomal aberrations found in lymphocytes taken from three
sets of patients are compared. Two patient groups were treated with the same
radiation quality, i.e. IMRT, and different target volumes, comparison of these
groups therefore provides information about the influence of different target
volumes. A third group of patients had a target volume similar to one of
the former groups, but was treated with a C-ion boost followed by IMRT.
Comparison of these two groups therefore yields information about the effect
of radiation quality.
Effect of target volume on aberration yield
In the data reported here, a pronounced influence of the target volume on the
aberration yield is visible (see Figure 3.12). A dependence of the aberration
yield on the target volume was previously observed by the use of PCC-FISH
for different tumor types and radiation qualities. Durante et al. [1999] and
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Yamada et al. [2000] investigated chromosomal damage in peripheral blood
lymphocytes of patients with esophageal carcinoma treated with X-rays using
two-color FISH. For 15 patients the fraction of aberrant peripheral blood
lymphocytes after 45 Gy X-rays to the target volume along the esophagus
was investigated and a linear increase of the fraction of aberrant cells with
increasing target volume was observed. In esophageal cancer, increasing the
field size proportionally increases the number of lymph nodes irradiated along
the lymph canal. As lymphocytes reside most of the time in the lymph nodes,
it is especially the number of lymph nodes in the field that determines the
fraction of irradiated lymphocytes. In a study published by Lee et al. [2004]
it was found that the fraction of aberrant cells in 22 lung cancer patients
at the end of C-ion treatment increases linearly with the target volume. In
a study with prostate cancer or endometrial cancer patients treated with
radiotherapy a correlation of dicentric yield with planning target volume and
mean bone marrow dose was found [Gershkevitsh et al., 2002]. D’Alesio et al.
[2003] reported in breast cancer patients that the aberration yield is not only
dependent on the target volume, but also on the number of lymph nodes
irradiated. This is in line with the study mentioned above [Yamada et al.,
2000] where it is concluded that especially the number of lymph nodes in
the field determines the fraction of aberrant cells. In the study reported
here the patients with the larger target volume showed a higher aberration
yield, the planning target volume for these patients included the pelvic lymph
nodes. Thus the findings of the previous studies are confirmed with the mFISH
method. However, whether the irradiated volume or the number of irradiated
lymph nodes is the major factor determining the aberration yield, or whether
both factors are equally important can presently not be determined.
Effect of radiation quality on aberration yield
One of the main goals of this study was to achieve information about the
different aberration yields and aberration patterns induced by C-ion boost
irradiation compared to IMRT. The present study revealed that at the end
of the C-ion boost irradiation the aberration yield was significantly lower in
the patients treated with the C-ion boost compared to patients irradiated
with IMRT with a comparable target volume (see Figure 3.13). This result is
highly relevant with respect to the increasing use of C-ion therapy worldwide.
As can be seen from the treatment plans shown in Figure 1.9, the volume
of irradiated normal tissue is smaller in case of C-ion boost irradiation (2
opposite irradiation fields, compared to 7 fields in case of IMRT) and this
is reflected by a lower aberration yield at the end of the C-ion boost. Such
an effect of C-ion irradiation compared to photon therapy was reported pre-
viously by Durante et al. [2000] in patients treated for uterus or esophageal
cancer by the use of two-color FISH. The lower cytogenetic toxicity of C-ion
therapy compared to a biologically equivalent tumor dose applied with IMRT
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is now confirmed with the full-genome paining mFISH. The whole-genome
analysis is of great importance as it ensures, in contrast to 1–3-color FISH,
that all types of chromosomal interchanges, including complex exchanges, are
detected. Concerns that C-ion radiotherapy may induce aberrations which
were underestimated with previous staining methods, e.g. a high fraction of
complex exchanges, can therefore now be dispelled.
As cytogenetic damage represents an indicator for the risk of late effects, it
can be expected from these findings that C-ion therapy induces less late effects
compared to IMRT. As mentioned earlier, late effects, which occur several
years after the therapy are increasingly important with the improvements in
cancer therapy leading to increased tumor control rates and longer patient
survival. Therefore, especially for young patients, C-ion tumor therapy can
be a good choice, as it provides good tumor control rates [Schulz-Ertner et al.,
2007a,b; Tsujii et al., 2008; Combs et al., 2009; Schulz-Ertner, 2009] and in
addition, as it is shown in the present study and in the study by Durante
et al. [2000], a lower risk of late effects, compared to IMRT, can be assumed.
4.3.2. Is there a fingerprint of C-ions in vivo?
The ratio of complex to simple exchanges (C-ratio) has been proposed as
a biomarker for densely ionizing radiation (see Section 1.3.6). The in vitro
experiments show an increased C-ratio after extended Bragg peak C-ion ir-
radiation, i.e. high-LET irradiation (see Section 3.1.4), in agreement with
previous in vitro studies [Durante et al., 2002; Wu et al., 2003; George et al.,
2003b; Johannes et al., 2004]. The C-ratio therefore seems to be a good cyto-
genetic marker for in vitro exposure to densely ionizing radiation (see Figure
3.4). However, in contrast to the in vitro results, no significant increase in
the C-ratio was observed in patients treated with C-ion boost, compared to
the IMRT patients in the present study (see Section 3.2.2). This is in line
with other studies, where no increase in the C-ratio was detected in vivo for
C-ion radiotherapy patients [Durante et al., 2004], mice exposed to Fe-ions
[Rithidech et al., 2007] or astronauts returning from long-term space flights
[George et al., 2003b]. A possible explanation for the different findings in
vitro and in vivo is the mixture of energies and corresponding LET values to
which a human or animal is exposed, as the particles change their energy while
traversing the body, in contrast to the more homogeneous beam energies ap-
plied in in vitro experiments. In the case of prostate cancer radiotherapy with
C-ions, the ions enter the body with an initial energy of about 300 MeV/u,
these ions induce a C-ratio which is similar to the one induced by X-rays, as
can be seen for the 270 MeV/u C-ions in Figure 3.4. The C-ions decelerate
on their way through the body and stop in the target volume, where they
are expected to induce a high fraction of complex aberrations, as can be seen
from the extended Bragg peak C-ion data in Figure 3.4. However, the stop-
ping C-ions are restricted to the target volume, which is small compared to
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the volume of irradiated normal tissue in the beam entrance channels. There-
fore, in vivo irradiation comprises a mixture of LET values and therefore a
mixture of corresponding C-ratios. Although it can be expected from the in
vitro experiments that the stopping C-ions induce a high fraction of complex
exchanges, this effect is overlaid by the low fraction of complex exchanges in-
duced in the entrance channel. The restriction of the high-LET region to the
tumor volume is highly desirable for radiotherapy, but for biological dosimetry
in cancer patients the use of the C-ratio as a biomarker for external exposure
to densely ionizing radiation is limited.
In contrast to the in vivo exposure to external radiation, where no bio-
marker for densely ionizing radiation is found, in studies that investigated
aberrations in individuals occupationally exposed to plutonium, a α-particle
emitter which is inhaled as dust by the exposed individuals, different results
were obtained. Hande et al. [2005] reported that complex aberrations have the
potential to be a biomarker for exposure to densely ionizing radiation. Ander-
son et al. [2005] also found that complex aberrations represent a biomarker
for α-particles. In contrast, in a study by Tawn et al. [2006] an increased
frequency of translocations was found in plutonium workers compared to in-
dividuals exposed to γ-rays, but no significant difference in the proportion of
complex aberrations. However, as single color FISH was applied in this study
complex aberrations may have been misinterpreted as simple ones [Cornforth,
2001].
4.4. Follow-up of radiotherapy - aberration
pattern and persistence of aberrations
Transmissible aberrations are of special interest for the monitoring of past
radiation exposure, as they persist in individuals for many years after expo-
sure. The aberrations induced in the in vitro experiments and in vivo in the
patients undergoing radiotherapy were investigated regarding their transmis-
sibility. The aberrations found one year after the therapy in the irradiated
patients were compared to this initial aberration pattern.
4.4.1. Aberration pattern
The aberrations induced in vitro and in vivo in peripheral blood lymphocytes
are listed in Tables 3.2 and 3.8. For the simple interchanges the induction rates
of transmissible and non-transmissible aberrations are similar, as predicted
theoretically by Lucas et al. [1996] (in the present work, 686 translocation
and 679 dicentric chromosomes were found after in vitro exposure and 347
translocation and 309 dicentric chromosomes were found in the patients during
and at the end of therapy). In contrast, for complex exchanges more non-
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transmissible than transmissible types were found after in vitro and in vivo
irradiation (again, see Tables 3.2 and 3.8).
In the year after therapy, the ratio of translocations to dicentric chromo-
somes increased from 1.03± 0.09 to 1.73± 0.21. A decrease in the aberration
yield can easily be explained by the death of some aberrant cells which are
replenished by dividing normal cells. A change in aberration pattern towards
stable aberrant cells on the other hand is an indicator for dividing aberrant
cells, i.e. irradiated bone marrow cells. During radiotherapy of the prostate,
bone marrow is exposed to some dose, especially the bone marrow in the hip-
bone and in the femur head [Gershkevitsh et al., 1999, 2005]. Bone marrow
cells carrying non-transmissible damage will die during the next few divisions,
while bone-marrow cells carrying a transmissible damage can pass this damage
to their daughter cells. Thus, the results of the present study show that the
irradiation of the bone marrow can be detected using cytogenetic methods.
4.4.2. Persistence of aberrations in vivo
Only few publications on the follow-up of cytogenetic damage in radiotherapy
patients using mFISH are available. Pouzoulet et al. [2007] analyzed aberra-
tions in two patients with head and neck cancer. Four sampling times were
used, the last one four to six months after therapy. In contrast to the method
used in the work presented here, the authors scored only those cells carry-
ing stable aberrations, cells with non-transmissible aberrations were excluded
from the analysis. Kuechler et al. [2003] reported the yield of aberrations
2–3 years after therapy in 12 patients, but did not analyze blood samples at
the end of therapy and all patients had received chemotherapy. Because of
these differences, these two studies are not suited for comparison with the
data presented here.
However, many studies exist where other staining methods (1–3-color FISH,
G-banding) were applied. Mueller et al. [2005] used three-color FISH to in-
vestigate the persistence of translocations in eleven patients with testicular
seminoma, germinoma and follicular non-Hodgkin’s lymphoma. In 9 of 11
cases a decline of translocation frequency was observed during a 36 months
period after therapy. In a study by Huber et al. [1999] both dicentrics and
translocation yields were scored using single-color FISH in five breast cancer
patients. A decline of the aberration yield was observed in two out of five pa-
tients during a 14 months period after therapy. Tawn and Whitehouse [2003]
reported translocation yields scored by G-banding in 8 patients with different
cancers up to 60 months after radiation therapy. Significant decrease was
observed in four patients.
In the study presented here, no significant decline in the year after the
therapy was observed when the pooled data of the three patient groups were
analyzed. When the decline of aberrations in the year after therapy was tested
in each patient individually, a statistically significant decrease was found in
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two out of 16 patients. These results are in line with the observations reported
by Huber et al. [1999], Tawn and Whitehouse [2003] and Mueller et al. [2005],
where in similar or longer time intervals a decline in aberration frequency was
observed in some patients only. The slow decline in aberration yield is caused
by the lifespan of the lymphocytes (lymphocytes consist of several subtypes
with lifespans ranging from a few days to several years [Pschyrembel, 2007])
and by the renewal of lymphocytes carrying aberrations by the offspring of
irradiated bone marrow cells. As pointed out in the previous section, a part
of the bone marrow is irradiated during radiotherapy of the prostate.
Studies exist that describe the presence of aberrations decades after radio-
therapy [Kleinerman et al., 1989, 1994]. In these studies blood samples were
taken from 96 cervical cancer patients 23 years after therapy and from 34 pa-
tients treated for benign gynecological diseases 40 years after therapy. These
time intervals are much longer than the mean half-life of blood lymphocytes
and the observed aberrant lymphocytes are assumed to be the progenies of
bone marrow cells that were exposed during the treatment. As lymphocytes
consist of several subpopulations, there are different half-life data published,
normally a half life between some weeks and a few years are determined exper-
imentally for the subpopulations [Tough and Sprent, 1995; Mclean and Michie,
1995; McCune et al., 2000; Macallan et al., 2003; Wallace et al., 2004]. The
cytogenetically aberrant bone marrow cells contribute to the risk of leukemia
as a secondary disease after therapy. Kleinerman found that the aberration
level observed long times after therapy is not proportional to the initial dose
to the bone marrow and is therefore not a biomarker for radiation dose, but it
appears to be a biomarker for the effective risk of the occurrence of leukemia.
In that study, the excess leukemia risk was about the same in both groups
although the cervical cancer patients received a much higher dose to the bone
marrow compared to the patients with benign gynecological diseases. High
doses are most likely lethal to the cells and therefore bone marrow cells re-
ceiving high doses will die while cells exposed th low doses receive non-lethal
damage and survive carrying cytogenetic damage. The volume of bone mar-
row irradiated during radiotherapy is therefore a major point together with
the applied dose when estimating the risk of secondary malignancies.
4.5. Involvement of individual chromosomes
Although it was outside the main purpose of this study, which was to in-
vestigate the cytogenetic damage induced by densely ionizing radiation in
in vitro experiments and in patients undergoing radiotherapy, an analysis of
the involvement of individual chromosomes in aberrations was carried out in
parallel to the normal mFISH aberration analysis.
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4.5.1. Distribution of breaks in individual chromosomes
The distribution of breakpoints in individual chromosomes was investigated
in the in vitro and in vivo experiments and compared to the chromosome
length and chromosome surface model (see Section 3.3.1). There was no
superiority of one model over the other observed. This is in line with the
findings in a recent publication by Lee et al. [2010], where the breakpoint
distribution in lymphocytes exposed in vitro to X-rays or 9.5 MeV/u C-ions
was investigated. This conclusion was also drawn by Durante et al. [2002]. In
other publications contradictory results are reported. Anderson et al. [2006]
and Lucas et al. [1992] found that the chromosome length model describes
their experimental data better, while Cornforth et al. [2002], Cremer et al.
[1996] and Cigarran et al. [1998] favor the chromosome surface model. To draw
a definitive conclusion whether one of both models describes the experimental
findings accurately, or whether other models must be considered, larger data
sets are necessary. The increasing use of mFISH and other whole-genome
painting techniques will hopefully lead to more investigations addressing this
topic in the future.
4.5.2. Insights in interphase chromosome positioning
Knowledge about chromosome territories in interphase cells is of interest to
understand the processes inside the cell nucleus. This includes the question
whether chromosome positioning depends on gene density or gene expression
[Parada and Misteli, 2002; Kuepper et al., 2007] and whether the chromosome
positioning is different for different species [Mora et al., 2006; Neusser et al.,
2007]. Laser scanning confocal microscopy and fluorescence microscopy con-
tribute mainly to the progress made in this field (for a overview see Walter
et al. [2006]). However, apart from the well-known localization of the acrocen-
tric chromosomes around the nucleoli [Krystosek, 1998; Sullivan et al., 2001;
Kalmarova et al., 2007] the positioning of other chromosomes remains unclear.
Another approach to address the positioning of chromosomes in the inter-
phase nucleus is made by the “statistics for chromosome interphase position-
ing based on interchange data” (SCHIP). If chromosomes are organized within
the cell nucleus in territories which form clusters and if misrejoining of dou-
ble strand breaks occurs mainly between neighboring chromosome territories
(i.e. “open ends” do not travel long distances before reconnection to other
ends [Jakob et al., 2009]), the chromosomal clusters should be detectable on
the basis of interchange data derived from the analysis of radiation-induced
aberrations using mFISH or similar whole-genome staining methods.
The data collected during the work presented here were used to create an
interchange table (based on about 5200 interchanges) and this was checked
for possible clusters using the SCHIP software. As it is known from differ-
ent publications, that the acrocentric chromosomes are located close to the
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nucleoli in the interphase nucleus, this cluster should be detectable using the
SCHIP. And indeed, a very low p-value < 0.0001 was found when testing this
cluster in the data collected from the work presented here, indicating a highly
significant deviation from the random model (see Table 3.9).
The cluster candidates reported in the literature, which are given on the
SCHIP homepage, were tested for significant deviation from the random model
in the data set obtained here. However, only four of them yielded p-values
below 0.05, indicating their spatial proximity. For the others, different reasons
for their occurrence may play a role. For example, the translocation between
chromosomes 9 and 22, known as the Philadelphia Chromosome found in
most chronic myeloid leukemia [Mitelman et al., 2007], shows a p-value of
0.07 in the present data set and 0.66 in the data set published by Arsuaga
et al. [2004], indicating that not the spatial proximity of both chromosomes is
the reason for their frequent occurrence in leukemia patients, but rather the
specific genes affected by the translocation.
In addition to the reported clusters, own candidate clusters were chosen
on the basis of the ∆(i, j) values. These 30 own candidate clusters were
tested for significance in the own data set, and all yielded p-values ≤ 0.01
(see Table 3.9). The same candidate clusters were then tested in the largest
lymphocytes data set provided at the SCHIP homepage, i.e. the data set
published by Arsuaga et al. [2004] (based on about 3700 table entries). From
the candidate clusters chosen on the basis of the data presented here, 80%
yielded p-values ≤ 0.05 in the independent data set provided by Arsuaga et al.
[2004]. This shows that it is possible to idetify chromosome clusters using the
method applied by the SCHIP software. Testing the clusters on three other
provided data sets (based on data obtained in the experiments described in
Loucas and Cornforth [2001]; Cornforth et al. [2002]; Durante et al. [2002]),
all of these tables having less entries (between 800 and 1900 table entries),
lead to rather disappointing results. Only four of the candidate cluster chosen
on the basis of the table reported here yielded p-values below 0.05 in all three
other tables (data not shown). The cluster of acrocentric chromosomes was
also not significantly different form a random distribution model in any of
these tables. This demonstrates that a successful search for clusters can only
be performed on very large data sets.
To overcome the subjective choice of candidate cluster and to show the
(possible) correlation between the table achieved from the present work and
the table published by Arsuaga et al. [2004], the ∆(i, j) values of the present
data set were plotted versus the ∆(i, j) values of the data set published by
Arsuaga et al. [2004]. The resulting Figure 4.2 shows a correlation, chromo-
somes that exchanged more frequent than expected from the random model
in one data set exchanged more frequent in the other data set as well and vice
versa. A linear function was fitted to the data (fit parameters p0 = 0.00±0.10
and p1 = 0.74±0.08). However, the large scattering proofs the need for tables
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with far more entries.
Figure 4.2.: ∆(i, j) values calculated by the SCHIP software for the table of
pairwise exchanges reported here plotted versus those calculated by SCHIP
for the data published by Arsuaga et al. [2004].
Altogether, it was demonstrated that clusters of chromosome territories in
the interphase nucleus exist, that misrepair of radiation-induced damage be-
tween neighboring chromosomes is more frequent than between distant chro-
mosomes and that it is possible to identify chromosome clusters using the
SCHIP principle. When large data sets are analyzed, the clustering of the
acrocentric chromosomes (which are known to be located in close proxim-
ity to each other around the nucleoli in the interphase nucleus) is confirmed.
Analysis of tables with less entries fails to confirm this cluster, underlining the
importance of large data sets. It was demonstrated that candidate clusters
chosen on the basis of one data sets yield statistically significant differences
from the random model in an independent data set, as long as sufficiently
large data sets are analyzed. For large data sets, a correlation between the
∆(i, j) values was demonstrated. This shows that the chromosome interphase
positioning is not donor-dependent.
An interesting topic for further research would be to compare data sets
obtained for other cell types (e.g. human fibroblasts) or other species (e.g.
peripheral blood cells from primates). There is also a need for larger data
sets for human peripheral blood lymphocytes to confirm the clusters obtained
so far and to search for additional ones. As the use of the mFISH method
increases, and tables with interchange data can easily be generated in parallel
to the normal aberration analysis there will hopefully be more (and larger)
interchange data sets published in the future. Then, it may be possible in the
future to derive a model of the interphase positioning of all chromosomes, ei-
ther directly from the mFISH data sets or by combining information achieved
from the interchange tables with results from fluorescence microscopy.

5. Summary and Outlook
Protons and C-ion beams are increasingly used in cancer therapy. C-ions are
ideally suited for the therapy of deep-seated radioresistant tumors as they
show, like all accelerated ions, an inverse depth dose profile compared to
photons. In addition, C-ions have the biological advantage of a high relative
biological effectiveness in the region of the maximal physical dose deposition.
The purpose of this study was to monitor the cytogenetic damage induced
in peripheral blood lymphocytes of prostate-cancer patients treated with C-
ion boost plus IMRT or IMRT alone and to perform in vitro experiments
with the radiation qualities relevant for the tumor therapy to achieve dose-
effect curves for the induction of chromosomal aberrations. The results of the
patient study were compared with the in vitro results. For the analysis of the
cytogenetic damage, the whole-genome mFISH method was used.
In the in vitro experiments it was found that the relative biological effec-
tiveness of C-ions for the induction of chromosomal damage increases with
increasing LET. For the first time, mFISH analysis was applied to measure a
set of dose-effect curves of heavy ions (Figures 3.2 and 3.3). The generated
data set now allowed determining the RBE for different aberration types. It
was found that the RBE for complex aberrations is higher than for simple
ones after 100 MeV/u and extended Bragg peak C-ion irradiation (Section
3.1.3). Regarding the spectrum of induced aberrations, an elevated ratio of
complex to simple exchanges (C-ratio), which is discussed as a biomarker for
densely ionizing radiation (see e.g. Johannes et al. [2004]), was found for
high-LET radiation and for high doses (Figure 3.4). Likewise, the complexity
of complex exchanges was found to increase with LET and dose (Figure 3.5).
The analysis of the completeness of aberrations showed, that the fraction of
incomplete exchanges increases with dose, in contrast to the findings by Lou-
cas and Cornforth [2001]. In addition, the fraction of incomplete aberrations
seems to increase with increasing LET (Table 3.3).
In the blood samples obtained from prostate-cancer patients undergoing
radiotherapy, an increase in aberration yield with therapy course was found
(Figure 3.12). This increase was most pronounced in patients treated with a
large target volume and hence with a larger volume of irradiated normal tissue.
Analysis of the aberration spectrum revealed that mainly simple chromoso-
mal aberrations were induced by the radiotherapy (Figure 3.13). Comparison
of blood samples obtained after the C-ion boost and after a comparable dose
of IMRT revealed that C-ion boost irradiation induces significantly less aber-
rations than IMRT. This observation was previously made by Durante et al.
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[2000] in esophageal cancer patients treated with C-ion therapy in Japan using
2-color FISH for the aberration analysis and is now confirmed with the mFISH
technique. The lower aberration yield found after C-ion boost is caused by
the lower integral dose to the normal tissue, compared to IMRT (see Figure
1.9). This underlines the superiority of C-ions for the treatment of deep-
seated tumors. Regarding the late effects of radiotherapy, it can be assumed
from the lower yield of induced cytogenetic damage that C-ion therapy causes
less late effects compared to IMRT. Regarding the presence of a cytogenetic
fingerprint of C-ions in vivo, it was found that no statistically significant in-
creased C-ratio was detected in the patients receiving C-ion boost irradiation.
In C-ion therapy, the high-LET region is restricted to the target volume. The
target volume receives very high doses, which are lethal for the tumor cells.
In the surrounding tissue, lower doses are applied and the cells are irradiated
with C-ions that have a lower LET. Thus, the induced damages are similar to
those caused by X-rays, as shown by the in vitro results of the present study
(Section 3.1). As the volume of irradiated normal tissue is larger than the
tumor volume (see Figure 1.9), most lymphocytes that float through the irra-
diation field receive low-LET irradiation rather than high-LET. In addition,
cell killing by the high doses in the high-LET region may play a role for the
lymphocytes. This explains the results of this study, where no biomarker for
high-LET irradiation was found in the patients receiving C-ion boost ther-
apy (Section 3.2.2). In contrast to radiotherapy patients, astronauts receive
low doses during space flights, therefore cell killing plays only a minor role.
Thus, the cytogenetic damage induced by high-LET exposure should be taken
into account for the estimation of the astronauts’ health risks [Durante and
Cucinotta, 2008].
One year after the therapy, a statistically significant decrease in the aberra-
tion yield was found in only two patients. Analysis of the aberration spectrum
showed that the fraction of transmissible aberrations increased during the year
after therapy (see Table 3.8), indicating that bone marrow cells were exposed
to radiation and aberrant bone marrow cells produce progenies carrying trans-
missible exchanges.
More information about the distribution of DNA damage in individual chro-
mosomes is of basic interest, as well as the exchange frequencies between chro-
mosome pairs after irradiation. The former provide a better understanding of
the induced damage and its repair in individual chromosomes (e.g. whether
gene-rich chromosomes are more sensitive or resistant to radiation than gene-
poor chromosomes). The latter provide information about the chromosome
positioning in the interphase cell nucleus, as neighboring chromosomes are
assumed to exchange more frequent than distant ones. The mFISH analysis
can give information about both, the distribution of breakpoints among indi-
vidual chromosomes and the exchange frequencies between chromosome pairs.
Therefore, albeit this was not the main topic of this study, these were analyzed
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in the in vitro and in vivo data. The distribution of breaks among individual
chromosomes was compared to the chromosome length and the chromosome
surface model. However, there was no superiority of one model over the other
observed (Figures 3.16 and 3.18). Therefore, in the future other models should
be considered, and larger data sets should be investigated. The distribution of
breaks was also compared to the gene density in the individual chromosomes,
but no correlation was visible (see Figure 3.17). The frequencies of pairwise
exchanges were analyzed using the “statistics for chromosome interphase po-
sitioning based on interchange data” software (SCHIP). The method was able
to confirm the known cluster of acrocentric chromosomes, indicating that the
method is functional and that the data set is sufficiently large to identify
chromosome clusters. Own candidate clusters were searched and tested for
statistically significant deviations from the random distribution model in the
present data set and in a published data set [Arsuaga et al., 2004]. All 30
candidate clusters yielded p-values below 0.01 in the present data set and 80%
of the candidate clusters yielded p-values below 0.05 in the published data set.
In addition, a correlation between the two data sets was shown (Figure 4.2).
These findings indicate that it is worth to spend more efforts in the generation
and analysis of interchange tables in the future.
Regarding the in vitro experiments, the complete C-ion energy range rele-
vant for tumor therapy was covered in the present work. Further work could
include the application of other staining techniques like multicolor banding
(mBand), which provides additional information about the ratio of intra- to
interchromosomal rearrangements, another possible biomarker for densely ion-
izing radiation.
In the future, further research related to the monitoring of the cytogenetic
damage induced by radiotherapy in peripheral blood lymphocytes would be
useful. Samples from the patients at later times than one year after therapy
should be analyzed. When a tumor therapy for prostate cancer applying
solely C-ions is performed in the future (in the HIT facility in Heidelberg
which started patient therapy recently1, or in the Partikel-Therapie-Zentrum
Marburg which is currently under construction2), it would be interesting to
compare the aberration yield found in these patients with the patient groups
analyzed in the present work. It would be definitely of importance to continue
the research on prostate cancer patients solely treated with C-ion irradiation
and to confirm the finding that C-ions therapy induces fewer aberrations in
the peripheral blood lymphocytes than IMRT.
1http://www.klinikum.uni-heidelberg.de/Startseite-HIT.113005.0.html
2http://www.rhoen-klinikum-ag.com/rka/cms/ptm/deu/index.html
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B. List of abbreviated terms
BrdU 5-bromo-2-deoxyuridine
CAB number of chromosomes, number of chromosome arms and number of
chromosome breaks involved in a complex aberration
DAPI 4’,6-Diamidino-2-phenylindol
DEAC 7-Diethylaminocoumarin-3-carboxylic acid
DNA deoxyribonucleic acid
DSB DNA double strand break
FCS foetal calf serum
FISH fluorescence in situ hybridization
FITC Fluorescein-5-isothiocyanate
FPG Fluorescence plus Giemsa
GS Gleason score
GSI GSI Helmholtzzentrum fu¨r Schwerionenforschung GmbH
GTV gross tumor volume
h hours
HIT Heidelberger Ionenstrahl-Therapie, ion beam facility in Heidelberg
HR homologous recombination
IMRT intensity modulated radiotherapy
LET linear energy transfer
M1 first mitosis
Mbp Mega-base-pairs, 1 · 106 base-pairs DNA
mFISH multiplex fluorescence in situ hybridization
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min minute(s)
MV mean value
NHEJ non-homologous end-joining
PAINT protocol for aberration identification and nomenclature terminology
PBS phosphate buffered saline
PCC premature chromosome condensation
PSA prostate-specific antigen
PTV planning target volume
RBE relative biological effectiveness
SCHIP Statistics for chromosome interphase positioning based on interchange
data
SD standard deviation
SIS heavy ion synchrotron at GSI (Schwerionensynchrotron)
SKY Spectral karyotyping
SpO Spectrum OrangeTM
SSA single strand annealing
SSC saline-sodium citrate buffer
TR Texas Red®
UV ultra-violett
C. Chemicals and laboratory
equipment
C.1. Chemicals
Acetic acid (Merck, Darmstadt)
5-Bromo-2’-deoxyuridine, BrdU (Serva, Heidelberg)
Citric acid (Merck, Darmstadt)
Colcemid, 10 µg/ml (Roche, Mannheim)
Disodium hydrogen phosphate: Na2HPO4 · 12H2O (Merck, Darmstadt)
Ethanol, absolute for analysis (Merck, Darmstadt; Applichem, Darmstadt)
Eukitt (O. Kindler, Freiburg)
Fetal calf serum (Biochrom, Berlin)
Giemsa (Merck, Darmstadt)
Hoechst No.33258 (Sigma, St.Louis, USA)
Hydrochloric acid (Merck, Darmstadt)
Isoton: Casyton (Schaerfe, Reutlingen)
Methanol, GR for analysis (Merck, Darmstadt)
mFISH kit: 24XCyte Human mFISH Probe Kit, (Metasystems, Altlussheim)
Natriumhydroxid NaOH (Sigma Chemie GmbH, Deisenhofen)
PBS without Ca2+ and Mg2+ (Biochrom, Berlin)
Penicillin/Streptomycin, 10000 E/10000 µg/ml (Biochrom, Berlin)
Phytohemagglutinin, PHA (Gibco, Paisley, UK)
Pepsin (Sigma, St. Louis, USA)
Potassium Chloride KCl (Merck, Darmstadt)
Potassium dihydrogen phosphate: KH2PO4 (Merck, Darmstadt)
RPMI 1640 medium (Biochrom, Berlin)
Saline-sodium citrate buffer (SSC) 20x (Applichem, Darmstadt)
Tween 20: Polyoxyethylene-sorbitan Monolaurate (Sigma, St.Louis, USA)
C.2. Disposable products
Cell culture flask: 25cm2 (BD Biosciences Franklin Lakes, USA)
Centrifuge tube: 15 ml (TPP, Trasadingen, Switzerland)
Centrifuge tube: 50 ml (Greiner, Frickenhausen)
Centrifuge tube for cell culture: 10 ml (Nunc, Roskilde, Denmark)
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Cover glass: 60 mm x 24 mm and 18 mm x 18 mm (IDL, Nidderau)
Microcentrifuge tubes (Eppendorf, Hamburg)
Pipettes: 2, 5, 10, 25 ml (BD Biosciences Franklin Lakes, USA)
Pasteur pipettes (Roth, Karlsruhe)
Microscope slides: 76 mm x 26 mm (Roth, Karlsruhe)
Tipps: 10, 200, 1000 µl (Brand, Wertheim)
Vacutainer CPT, Cell preparation tube (Becton Dickinson, Franklin Lakes,
USA)
C.3. Laboratory equipment
Autoclave: Varioklav-Dampfsterilisator (H+P Labortechnik, Oberschleissheim)
Centrifuge: Megafuge 1.0 (Kendro-Heraeus instruments, Hanau)
Cell counter: Casy 1 model TT (Schaerfe system, Reutlingen)
Clean bench: Hera Safe HSP12 (Kendro-Heraeus instruments, Hanau)
Fluorescence microscope: BX61 (Olympus, Tokyo, Japan)
Hybridization oven: Unitherm oven 6/12 (Kisker, Steinfurt)
Incubator: BBD6220 (Kendro-Heraeus instruments, Hanau)
Pipettes: Eppendorf research (Eppendorf, Hamburg)
Pipette aid: Pipetboy Plus (Integra Bioscience, Fernwald)
Ultrapure water supply-system: Milli-Q Plus (Millipore, Eschborn)
UV lamp (Novodirect, Karlsruhe; Bioblock scientific, Illkirch, France)
Water bath: M12, M20 (Lauda, Lauda-Koenigshofen)
X-ray machine: IV320-12 (Seifert, Ludwigshafen)
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